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Type 2 Diabetes Mellitus  
Type 2 Diabetes Mellitus (Type 2 DM) is a growing public health threat demonstrated by 
a dramatic increase in number of patients in the world. With approximately 194 million 
diabetic patients in 2003, this number is predicted to increase to 333 million by 2025 [1] 
due to improved life expectancy, population growth, and progressive urbanization. Type 
2 DM increases the risk of hypertension and associated macro- and 
microcardiovascular diseases, including coronary, cerebrovascular, renal, and 
peripheral vascular disease [2]. Cardiovascular disease accounts for up to 80% of the 
deaths in individuals with Type 2 DM. The mortality associated with cardiovascular 
disease is reported to be 7.5 times greater among persons with Type 2 DM without a 
previous myocardial infarction than in those without diabetes [3]. Due to the difficult 
diagnosis of diabetes in early stages, and consequently initiation of proper treatment, 
the risk of diabetes-related complications is increased. It is estimated that approximately 
25% of diabetics in the United States (US) are unaware of their condition [4]. 
Therefore, diabetes and its associated complications have a significant cost burden on 
society. For example in the US direct and indirect medical costs (due to work loss, 
disability, and premature mortality) have been estimated at $176 billion and $64 billion, 
respectively, for 2012, which is a tremendous increase compared to $116 billion and 
$58 billion, respectively, for 2007 [4,5]. Diabetic patients spend more time on health 
care services, thereby increasing healthcare costs [5], while the loss of working days 
leads to loss of productivity [6,7].  
Introduction  
 
7 
Pathophysiology 
The mechanistic background for the disease is an imbalance between increased insulin 
requirement (insulin resistance) versus insufficient insulin availability (insulin deficiency) 
resulting in hyperglycemia and increased circulatory fatty acids. Figure 1 illustrates the 
main pathophysiological factors and consequences of Type 2 DM. 
 
Biologically, insulin resistance can be defined as diminished tissue response to insulin 
at one or more sites in the complex pathways of hormone action despite higher than 
normal plasma insulin levels (also known as compensatory hyperinsulinemia) [8]. Insulin 
Figure 1 Pathogenesis and cardiovascular complications of Type 2 DM  
 
Genes Environment / Lifestyle 
               Insulin resistance 
adipocytes          release of non-esterified fatty acids 
liver                    excess glucose production 
skeletal muscle  impaired insulin-mediated glucose clearance  
 
Insulin deficiency 
pancreatic -cell dysfunction   inhibited insulin secretion 
Hyperglycemia  Non-esterified fatty acids release 
Macrocardiovascular complications 
     coronary artery disease 
      peripheral artery disease 
      stroke 
      amputation 
 
Microcardiovascular complications 
retinopathy 
microalbuminuria 
nephropathy 
neuropathy 
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resistance is strongly associated with obesity and physical inactivity, and several 
mechanisms mediating this interaction have been identified. A number of circulating 
hormones, cytokines, and metabolic fuels, such as non-esterified (free) fatty acids 
(NEFA), originate in the adipocyte and modulate insulin action. Adipocytes can become 
overly large due to increase of stored triglycerides and as a result become resistant to 
insulin. Not regulated by insulin, adipocytes will release NEFA and glycerol, both of 
which will contribute to aggravate insulin resistance in skeletal muscle and liver [9].  
Insulin deficiency is characterized by an abnormal insulin secretion pattern due to a 
pancreatic -cell defect. Normal -cell response to glucose is characterized by an early 
burst of insulin (first phase) release and a second phase characterized by a progressive 
increase in insulin secretion lasting several hours. The first phase is important as it 
inhibits the glucose release from the liver, and, thus contributes to the maintenance of 
normal glucose tolerance. The loss of the first phase insulin secretion can be used as a 
marker of -cell dysfunction and can precede and predict overt Type 2 DM [8,10-12]. 
Potential mechanisms leading to -cell dysfunction include reversible metabolic 
abnormalities (glucotoxicity, lipotoxicity), hormonal change (inadequate incretin action, 
increased glucagon secretion), genetic abnormalities of -cell proteins, and reduction of 
-cell mass (apoptosis) [8].  
Treatments  
Treatment of Type 2 DM is aimed at increasing β-cell function and lowering insulin 
resistance in order to lower blood glucose levels. The initial therapy is targeted towards 
improving tissue insulin sensitivity due to its fundamental role in the pathogenesis of 
Type 2 DM and its relationship to adverse cardiovascular outcomes. This includes life 
style intervention with modest exercise and weight loss, as well as various oral and s.c. 
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hypoglycemic agents, used either as mono- or combination therapy. Table 1 provides 
an overview of treatments available for Type 2 DM. Though most antidiabetic drugs are 
in general well tolerated, some risks remain. While serious side effects can be 
monitored and are infrequent, less serious side effects such as weight gain may affect 
patient compliance [13-15]. Also, while better treatments are available that control 
glycemic abnormalities and high blood pressure in Type 2 DM, there remains a high 
rate of cardiovascular and, specifically, renal risk within the diabetic population [16-18]. 
Therefore, there is a need for better and safer antidiabetic drugs. 
New approaches to treatment of Type 2 Diabetes Mellitus 
Diabetic nephropathy has become the leading cause of end-stage renal disease in the 
United States and Europe, accounting for approximately 40% of new cases in the 
United states [19] and up to 20% in Europe [20]. The earliest clinical manifestation of 
diabetic nephropathy is the development of low but abnormal levels of albumin in the 
urine (albuminuria). If not treated, microalbuminuria will progress to proteinuria, which 
correlates with a decline in renal function [16,21,22].  
The underlying mechanism linking albuminuria and chronic renal failure has not been 
completely elucidated. It has been observed that systemic hypertension accelerates 
progression of diabetic nephropathy, and lowering blood pressure reduces renal 
damage. Indeed, reducing blood pressure with renin-angiotensin-aldosterone system 
blockers (RAAS blockers) has demonstrated protection of patients from cardiovascular 
and renal events [16,23]. However, these studies also showed that reduction of blood 
pressure cannot completely account for the therapeutic effect. Most likely albumin 
directly impacts chronic tubulointerstitial damage by eliciting pro-inflammatory and pro-
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fibrotic effects through several pathways [21,24]. One of those pathways may be the 
urotensin-II (U-II) system. 
 
Table 1 Current diabetic medications and drawbacks 
Drug Class Mechanism of Action Side Effects 
Thiazolidinediones ●  Increase in hepatic insulin sensitivity 
●  Increase in muscle insulin sensitivity 
●  Suppression of NEFA release 
●  Fat redistribution (visceral to subcutaneous) 
Hepatic injury 
   
Metformine ●  Inhibition of glucose production 
●  Increase in hepatic insulin sensitivity 
GI effects 
Lactic acidosis 
   
α-glucosidase inhibitors  ●  Inhibition of glucose absorption 
●  Stimulation of GLP-1 release 
Hepatic injury 
   
Sulfonylurea derivatives ●  Acute stimulation of insulin release Hypoglycemia 
Weight gain 
   
Exogenous insulin ●  Inhibition of glucose production 
●  Increase in muscle insulin sensitivity 
Hypoglycemia 
   
Metglinide ●  Acute stimulation of insulin release Hypoglycemia 
   
GLP-1 analogues ●  Acute stimulation of insulin release 
●  Stimulation of insulin biosynthesis 
●  Inhibition of -cell apoptosis 
●  Stimulation of -cell differentiation 
GI effects 
   
Amylin analogues ●  Delay of gastric emptying 
●  Inhibition of glucagon release 
GI effects 
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Objectives of this thesis 
The thesis focuses on the urotensin-II (U-II) system and its relevance to Type 2 DM 
treatment (Part I), the clinical pharmacology of the urotensin-II receptor (UT receptor) 
antagonist palosuran (Part II) in healthy subjects, and the clinical pharmacology of 
palosuran in Type 2 DM (Part III). Palosuran is a non-peptide, oral, selective UT 
receptor antagonist that was the first in its class that was tested in humans. The thesis 
will discuss the pharmacokinetics and pharmacodynamics in healthy subjects, as well 
as pharmacokinetic and clinical data in patients, which contributed to the clarification of 
the (patho)physiological role of U-II. 
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Urotensin-II 
The first reports on Urotensin-II (U-II) were published in 1969 by Bern et al., when they 
identified a urophysial peptide isolated from an extract of goby fish, Gillichthys mirabilis 
[1]. It was not until the nineties that the function of this peptide was further elucidated. In 
fish, U-II is involved in cardiovascular regulation, osmoregulation for seawater 
adaptation, and the regulation of lipid metabolism [2]. For many years considered a 
potent vasoconstrictor in lower organisms and fish, interest in this system was low until 
homologs were identified in mammals [3] and Ames et al. cloned a novel human G-
protein-coupled receptor for U-II [4]. This human receptor GPR14 was later renamed 
urotensin (UT) receptor and revived the interest in this field [4-6].  
In humans U-II is composed of 11 amino acid residues which is shown in Figure 1 [7,8]. 
Across species the peptide exhibits a cyclic portion comprising six amino acids linked by 
cysteine disulfide bridges (Figure 1), indicating that this region is responsible for the 
biological activity [7-9].  
U-II derives from pre-pro U-II, which contains 124-139 amino acid residues. The 
identity, location, and regulation of urotensin converting enzymes (UCE) which form 
biologically active human U-II (hU-II) from pro hU-II have only recently been 
investigated with furin and trypsin able to convert a 25 amino-acid C-terminal fragment 
of pro hU-II [9]. Furin plays a role in the cleavage of a number of precursor hormones 
including human pro endothelin-1 and human pro parathyroid hormone, and is 
characterized by sensitivity to pH, and to the ionic composition within its surrounding 
milieu. However in assays, in which recombinant furin activity was inhibited by low pH 
and altered ionic composition of medium, some residual intracellular UCE activity 
remained, suggesting additional endogenous U-II convertases [9]. 
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As UCE activity is mainly present in intracellular compartments, similarly to endothelin 
converting enzyme, processing of the U-II prohormone occurs within cells, with mature 
peptide secreted from the cells [9].  
U-II and UT receptor are strongly expressed in the CNS but also widely expressed 
throughout peripheral tissues including the heart, vasculature (endothelial and smooth 
muscle), kidney, liver, adrenal, and other sites. Such distribution suggests that U-II is a 
potential autonomous regulator of cardiovascular function [10,11]. Furthermore, the 
presence of circulating U-II in blood indicates that U-II might also be an endocrine factor 
[3]. 
Figure 1 Examples of the amino acid sequences of mammalian, 
amphibian, and fish U-II.  
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Although the amino acid terminus of U-II differs between species, all isoforms share a conserved cyclic hexapeptide (as 
marked in the shaded box) 
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Biological response to U-II in the vascular system 
Human U-II induced potent and efficacious contractions of the isolated thoracic aorta of 
rat, with an order or magnitude larger than other vasoactive peptides such as 
endothelin-1, noradrenaline, and serotonine [4]. Thus, U-II is the most potent 
vasoconstrictor identified up to date [4,7]. However, it was observed that response to U-
II varies between species, between types of blood vessel, and even between individual 
vessels of the same type, which is unlike the response of vascular tissues to endothelin-
1 and make the role of U-II in vascular systems more difficult to predict [5]. 
Through binding to the UT receptor, U-II activates the inositol trisphosphate system 
leading to the release of intracellular calcium and, consequently, vasoconstriction. 
Additionally, vasoconstriction is mediated by ERK1/2 and RhoA/Rho kinase related 
pathways [12]. These two pathways are also important in vascular smooth muscle cell 
proliferation and migration [13]. On the other hand, U-II also demonstrated endothelium-
dependent vasodilatory properties through nitric oxide, Prostaglandin I2, Prostaglandin 
E2, and endothelium-derived hyperpolarizing factor (EDHF) release [12]. A schematic 
overview of the vascular urotensin system is given in Figure 2.  
Activity of hU-II in vitro and in vivo 
The effects of U-II have been studied in different mammalian species in a number of in 
vitro and in vivo systems. Depending on the species and vessel studies, contrasting 
responses have been observed (Table 1). The most obvious explanation for this 
variability is that the level of receptor expression is low and possibly absent or below the 
density required to elicit a response to the peptide. Age might be another contributing 
factor as it has been observed that the effect of U-II on vascular smooth muscle 
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contraction in aorta diminishes with age in rats [14]. Also, the initial contractility studies 
and vascular smooth muscle cell proliferation experiments with U-II were performed with 
rat aorta or cultured rat aortic vascular smooth muscle cells. The contractile responses 
of the aorta to U-II are atypical as the efficacy of U-II in this vessel is much higher than 
in many other isolated blood vessels. In these studies, vascular preparations often were 
stripped of endothelium, which is certainly not physiological. It is therefore possible, that 
Figure 2 Summary of the intracellular pathways of U-II mediated 
vasoconstriction, proliferation, and migration.  
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AA = arachidonic acid; ACAT-1 = acyl-coenzyme A:cholesterol O-acyltransferase-1; Akt = serine/threonine protein kinase B; 
c-Src = Src kinase; Ca
2+
 = calcium; DAG = diacylglycerol; EDHF = endothelium-derived hyperpolarizing factor; ERK = 
extracellular signal regulated kinase; IP3 = inositol trisphosphate; MAPK = mitogen-activated protein kinase; MLCK = myosin 
light chain kinase; NADPH = nicotinamide adenine dinucleotide phosphate-oxidase; NO = nitric oxide; PGI2 = prostacyclin I2; 
PKC = protein kinase C; PLA2 = phospholipase A2; PAI-1 = plasminogen activator inhibitor-1; PLC = phospholipase C; 
ROCK = rho kinase; ROS = reactive oxygen species; U-II = urotensin-II; UCE = urotensin converting enzyme; UT = 
urotensin receptor. 
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the vasoconstriction is in part related to the experimental conditions and may not be 
relevant to in vivo effects [15]. 
To date, only few studies have investigated the function of hU-II in an in vivo setting 
(Table 2). Also in these studies, the in vivo vasocontrictor activity of hU-II in rats, 
monkeys, and humans was not consistent among studies and seems to be dependent 
on the animal model used, differences in species, and method of delivery [16]. These 
differences become very evident in in vivo studies in humans. Following infusion of hU-II 
in the brachial artery, Böhm et al. reported potent, significant reduction in forearm blood 
flow. However, using a very similar methodology, Wilkinson et al. could not detect any 
effects of hU-II [17,18]. As these studies were performed in healthy subjects, the true 
importance of U-II in vivo may only be fully evaluated in pathology, for example when 
endothelial cell function is compromised, in diffuse peripheral arterial disease, or under 
circumstances in which the UT receptor system is upregulated [9]. This seems to be 
supported by the findings of Lim et al., who showed a difference in hU-II skin 
microcirculation response between healthy subjects and patients with chronic heart 
failure [19].  
U-II in cardiovascular disease 
Atherosclerosis 
In the Apolipoprotein E gene knockout mouse model of atherosclerosis, an increase in 
UT receptor expression was observed in aortic tissue [37]. A selective induction of UT 
expression in vascular smooth muscle cells in these mice resulted in far greater aortic 
lesions when compared to wild-type mice [38]. Although no difference in UT expression 
has been observed between vascular smooth muscle cells of healthy humans and 
patients with atherosclerotic coronary arteries, increased expression of UT receptors 
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has been observed in human abdominal aortic aneurism and carotid atherosclerotic 
extracts [39,40]. Further, plasma U-II levels are elevated in patients with confirmed 
atherosclerosis [41]. It has been suggested that U-II is involved in the control of vascular 
 
 
Table 1 Vascular responses to hU-II in vitro.  
Species Vascular tissue  Response to hU-II Reference 
Mouse Thoracic and abdominal aorta Unresponsive [20,21] 
    
Rat Thoracic aorta Vasoconstriction [4,20,22] 
 Femoral, mesenteric, renal, and 
abdominal aorta 
Unresponsive [4,22] 
 Carotid and coronary arteries Vasoconstriction [21,22] 
    
Guinea pig Thoracic aorta Unresponsive [23] 
    
Rabbit Thoracic aorta; coronary artery Vasoconstriction [24] 
 Pulmonary and ear arteries; ear veins Unresponsive [24] 
    
Dog Coronary artery Vasoconstriction [20,21] 
 Thoracic aorta Unresponsive [20,21] 
    
Pig Coronary, renal, mammary, and carotid 
artery; saphenous vein 
Unresponsive [20,21] 
    
Marmoset Thoracic artery Vasoconstriction [20,21,23] 
    
Cynomolgus 
monkey 
Coronary, pulmonary, renal, femoral, 
mesenteric, internal mammary, basilar 
arteries; thoracic and abdominal aorta 
veins 
vasoconstriction [4,20,21,25] 
    
Human Coronary, radial, and mammary arteries; 
pulmonary arteries (endothelium 
removed) 
Vasoconstriction [25-27] 
 Vessels (endothelium intact) Unresponsive [11] 
 Umbilical, facial, epigastric, and 
saphenous veins (endothelium removed) 
Vasoconstriction [23,27] 
 Saphenous veins Unresponsive [25] 
 Small pulmonary and abdominal adipose 
tissue arteries 
Vasodilation  [28] 
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Table 2   Vascular responses to hU-II in vivo. 
Species Model Route of administration Result Reference 
Rat Anesthesized rat Bolus i.v. Vasodepressor response 
Concomitant tachycardia 
[29]  
 Conscious rat Bolus i.v. Dose-dependent tachycardia 
Vasodilatation 
[30] 
Sheep Conscious ewes Intracerebroventricular 
infusion 
Increase in adrenocorticotropic hormone and 
adrenaline levels; increased cardiac output; 
increased arterial pressure, peripheral 
vasodilatation; hyperglycemia 
[31] 
 Conscious ewes Bolus i.v. Tachycardia; reduced cardiac stroke volume [31] 
Cynomolgus 
monkey 
Anesthetized monkey Bolus i.v. Systemic vasoconstriction; severe myocardial 
depression;fatal circulatory collapse 
[4,32] 
Human  
 
Forearm blood flow study in 
healthy subjects 
Local infusion Dose-dependent reduction in forearm blood flow [17] 
 Forearm blood flow study in 
healthy subjects 
Local infusion No effects 
 
[18,33] 
 Cutaneous microcirculation in 
healthy subjects and patients with 
chronic heart failure 
Iontophoresis Healthy subjects: vasodilatation;  
Patients: constriction of forearm skin 
microcirculation 
[19] 
 Cutaneous microcirculation in 
healthy subjects and patients with 
essential hypertension 
Iontophoresis Healthy subjects: vasodilatation;  
Patients: vasodilatation / vasoconstriction 
[34] 
 Cutaneous microcirculation in 
healthy subjects and patients with 
essential hypertension 
Iontophoresis Healthy subjects: vasodilatation;  
Patients: vasoconstriction 
[35] 
 Cutaneous microcirculation in 
healthy subjects and patients with 
liver cirrhosis 
Iontophoresis Healthy subjects: vasodilatation;  
Patients: constriction of forearm skin 
microcirculation 
[36] 
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remodeling by inducing smooth muscle cell proliferation and fibroblast-mediated 
collagen deposition, which play an important role in the etiology of atherosclerosis [42-
44]. In addition, inflammatory compounds such as LPS, TNF-α, and IFN-γ all upregulate 
UT receptor mRNA expression [45], alluding to the chemotactic and signaling roles that 
U-II may play in the progression of atherosclerosis. 
Congestive heart failure (CHF) and other cardiac diseases 
Myocardial remodeling, including hyperthrophy, apoptosis, interstitial fibrosis, and 
vascular endothelial cell dysfunction are factors that contribute to the pathogenesis and 
progression of CHF.  
U-II expression and U-II plasma levels are increased in many types of cardiac disease. 
In a rat coronary ligation model of left ventricular myocardial infarction, pre-pro U-II 
mRNA and expression of UT receptors was elevated in the non-infarct and infarct 
regions with preferential up-regulation in the right ventricle [9,42,46]. This is in line with 
the observation of preferential up-regulation of UT receptors in the right ventricle of rats 
with right heart failure secondary to pulmonary hypertension [47]. Similar observations 
have been reported in humans; U-II and UT receptor expression were increased in 
proportion to disease severity in infarct and non-infarct zones of patients with 
myocardial infarction [42]. 
Several studies have demonstrated that overexpression of the UT receptor system or 
stimulation with U-II produced a hypertrophic phenotype in cultured rat neonatal 
cardiomyocytes [42,48]. A mechanism for U-II mediated hypertrophy may also involve 
the stimulated release of cytokines from cardiac myocytes. Rat cardiac myoblasts 
overexpressing UT receptors were incubated with U-II resulting in an increase in 
interleukin-6 and the development of a hypertrophic phenotype [49].  
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In myocardial specimens from patients with CHF, immunohistochemical analysis 
demonstrated strong cardiomyocyte expression of U-II and UT receptors [50]. The 
presence of U-II in the cardiomyocytes correlated significantly with left ventricular end-
diastolic volume and was inversely correlated with ejection fraction. A subsequent study 
found that U-II plasma levels are also significantly elevated in patients with CHF, and 
that U-II levels are inversely correlated to ejection fraction [51] or correlated with 
severity of disease as measured by New York Heart Association functional class [52]. 
However, there are also study reports in which levels of U-II were not significantly 
elevated [53].  
U-II is also clearly implicated in coronary artery disease [54], left ventricular systolic [52] 
and diastolic [55] dysfunction and myocardial infarction [32] in humans. Lastly, plasma 
U-II levels correlate positively with ET-1, adrenomedullin, and N-terminal brain 
natriuretic peptide [50,56].  
Essential Hypertension 
The role of the U-II system in the development of essential hypertension is unclear. 
Indeed, systemic hypertensive responses to U-II were observed in several animal 
models. However, these effects were not uniform across species [30,57] and were 
mostly observed in the absence of an intact endothelium. Therefore, the contribution of 
U-II to hypertension is most likely revealed under conditions of co-existing 
cardiovascular disease in which endothelial dysfunction is prevalent. In what can be 
thought of as a cause-and-effect relationship, U-II causes potent vasoconstriction 
leading to hypertension. Hypertension in turn increased turbulent hemodynamic flow 
and shear stress on the endothelium leading to endothelial damage and endothelial 
dysfunction. This endothelial dysfunction then further comprises the arterial system [58]. 
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Increased plasma U-II levels have been observed in spontaneously hypertensive rats 
[59] as well as in hypertensive patients [60], suggesting an up-regulation. 
Pulmonary hypertension 
Pulmonary hypertension is a multifactorial disorder characterized by vasoconstriction 
and pulmonary vascular remodeling [61]. An activated UT receptor system may 
contribute to the pathogenesis of pulmonary hypertension by remodeling of the 
pulmonary vasculature. Hypoxia is a well-known cause of pulmonary hypertension. 
Although one study in chronically hypoxic rats did not observe any increase in plasma 
U-II levels [47], in another study hypoxia was found to specifically increase U-II in 
endothelial and smooth muscle cells in the pulmonary arteries of rats [47,62]. The 
function of U-II in pulmonary hypertension in humans has not been elucidated and data 
on this topic is not consistent. As previously mentioned, the actions of U-II on the 
pulmonary circulation are quite variable. Although U-II did not change pulmonary artery 
perfusion pressure in human isolated perfused lungs, it may be, again, due to masking 
of the effect by U-II stimulated nitric oxide synthase activity in the endothelium. As 
endothelial dysfunction is prevalent in patients with pulmonary hypertension [63,64], U-II 
could still contribute to the pathogenesis of this disease.  
Hepatic Disease 
It is known that vasoconstrictive substances are important in liver pathologies such as 
portal hypertension [36,65]. First evidence that U-II may have a pathological role in 
chronic liver disease has recently been published. In normal rats, continuous infusion of 
U-II over a time period of 4 weeks induced a significant dose-dependent increase in 
portal venous pressure. Other effects were an up-regulation in the hepatic transcript for 
transforming growth factor- and platelet-derived growth factor- (both key profibrotic 
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cytokines) and liver fibrosis as demonstrated by increased hepatic hydroxyproline 
[36,65]. Liu et al. observed an increase in UT mRNA in liver tissue of cirrhotic patients, 
when compared to healthy controls. Plasma U-II levels in patients with cirrhosis and 
portal hypertension were significantly increased and correlated with the extent of portal 
hypertension [66,67]. Baseline plasma U-II may be used as a predictive marker for 
determination of survival or disease deterioration [36].  
Adrenal Tumors and other Cancer Types 
Cancer may be another field in which the U-II system may play a role. U-II and UT 
receptor mRNA is expressed in several adrenal tumor cell lines (including 
adrenocortical carcinoma), cervical cancer, and renal carcinoma cells [68,69]. In 
particular, substantial U-II and UT expression alterations were observed in a number of 
adrenal cancers [70]. U-II and UT receptor mRNA have both been detected in human 
lung adenocarcinoma cells. Administration of U-II to nude mice bearing human lung 
adenocarcinoma cells resulted in a significant increase in tumor volume and tumor 
weight [71]. In prostate adenocarcinoma cells of cancer patients, UT receptor mRNA 
was always expressed in hyperplastic tissues and at high intensity in well-differentiated 
carcinoma. When stimulating the cells with urantide (a U-II agonist) in vitro cell motility 
was decreased and invasion by androgen-dependent LNCaP cells was increased. 
These findings suggest that U-II may contribute to the pathogenesis of different tumor 
types by acting as an autocrine/paracrine growth stimulating factor [58,72] and in some 
cancers may be utilized as a prognostic marker [73]. 
Protective effects of U-II 
An emerging concept proposes that the observed increases in U-II levels in a number of 
cardiovascular and renal diseases may actually be protective in nature. Although, as 
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discussed earlier, many reports indicate increased U-II levels in disease when 
compared to the physiological condition in some individuals a high U-II level appears to 
correlate with a protection against inflammation, endothelial dysfunction, and 
cardiovascular adverse events (AEs). For example, when compared to patients with 
stable coronary artery disease and with healthy subjects, those patients with acute 
cardiac ischemia displayed lower circulating levels of U-II [74]. There may also be a 
protective effect from high U-II levels in post-MI patients, as higher levels are associated 
with a lower risk of AEs [75]. Proposed mechanisms are the effect of U-II on the 
sympathetic and NO system, as well as a beneficial effect on volume overload and 
myocardial contractility [76]. Futher studies using UT receptor antagonists or adopting a 
prospective study design are needed to understand better the functional roles of U-II. 
Summary and outlook 
Since the discovery of U-II and the UT receptor in humans some 20 years ago much 
work has been done to further characterize the role and mechanism of action of U-II in a 
variety of diseases. UT receptor antagonism may become a significant therapy for a 
number of diseases. Another field of specific interest, which was not discussed in this 
chapter, is the role of the U-II system in renal diseases (including metabolic syndrome 
and Type 2 DM). With rising numbers of patients suffering from renal disease, metabolic 
syndrome, and type 2 DM and current treatments not fully addressing the need of these 
patients, U-II antagonism might be an interesting new approach to treatment.  
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Introduction 
In the previous chapter U-II and its role in cardiovascular disease were discussed in 
detail. This chapter will focus on the role of U-II in renal disease which includes 
metabolic syndrome, Type 2 DM, and end stage renal disease. The metabolic 
syndrome is a cluster of metabolic abnormalities, including central (abnormal) obesity, 
raised fasting glucose, raised blood pressure, raised triglycerides, and reduced HDL 
cholesterol. It is associated with insulin resistance, endothelial dysfunction as well as 
prothrombotic and proinflammatory status, which are themselves independent risk 
factors for cardiovascular disease and diabetes [1,2]. Type 2 DM is a metabolic disease 
characterized by insulin resistance and insulin deficiency caused by a defective 
pancreatic β-cell response to glucose. The physiological and pathological roles of U-II in 
animals and humans in these diseases will be reviewed as well as the effects of the U-II 
receptor antagonist palosuran in animal models of renal disease. 
Biological response to U-II in the kidney, liver, pancreas, and CNS 
In the previous chapter the effect of U-II on vascular tone has been described in detail. 
Besides the cardiovascular effect, U-II is considered to have other properties that 
contribute to renal and metabolic disease.  
The kidney plays a pivotal role in controlling cardiovascular homeostasis, and influences 
both cardiac preload (plasma volume) and afterload (peripheral resistance) through 
regulated natriuresis and diuresis and the control of vasomotor tone. In addition to 
acting as a potent renal-artery spasmogen, U-II may directly regulate transepithelial 
transport of electrolytes. While this effect has been observed in fish, it has not yet been 
fully investigated in other species. However, the finding that, in rats, renal blood flow 
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and urinary water and Na+ increased after U-II infusion, indicate a possible role of U-II in 
Na+ ion transport in the collecting duct [3].  
U-II and UT receptor have been identified in liver and pancreas and may have direct 
effects on glucose mobilization and insulin secretion by pancreatic  cells. In the central 
and peripheral nervous system U-II has been associated with increased release of 
adrenocorticotropic hormone (ACTH) and adrenaline through sympathoadrenal and 
pituitary-adrenal pathways [4]. ACTH stimulates release of cortisol, which mediates 
renal vasodilatation [4-6]. Release of ACTH is accompanied by sustained 
cardiovascular and metabolic changes, including hyperglycemia as a result of cardiac -
adrenoceptor stimulation [7]. The increase in ACTH leads to an increase in insulin 
secretion. Insulin, besides its metabolic effects, induces endothelium-dependent 
vasodilatation and increases glucose uptake in peripheral tissues. It is possible that U-II 
impairs both of these actions and causes insulin resistance similar to endothelin-1 [8]. 
U-II is associated with an increase in plasma free fatty acids and enhances lipogenesis 
by increasing glucose-6-phosphate dehydrogenase activity and NADP production. U-II 
enhances depot lipase activity, which may lead to hyperlipidemia. Further, U-II may 
contribute to insulin resistance through its inflammatory effects and promotion of 
endothelial dysfunction [9]. 
UT receptor mRNA is found in the hypothalamus, which plays a major role in sleep and 
feeding behavior [10].  
Limited information of the effects of U-II on the liver, pancreas, and renal function is 
available. Also, most studies were performed with U-II of mammal or amphibian nature, 
making it challenging to interpret the data and evaluate its relevance to humans. An 
overview of studies performed with hU-II in vitro and in vivo is shown in Tables 1 and 2. 
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Table 2 Responses to hU-II in vivo. 
Species Model  
hU-II route of 
administration 
Result Reference 
Rat Anesthesized 
rat 
Continuous 
infusion 
No effect on mean arterial 
pressure; dose-dependent 
increase in renal blood flow, 
glomerular filtration rate; and 
urinary water/sodium excretion. 
All effects blocked by  L-NAME 
 
 
[3] 
Man Cutaneous 
microcirculation 
in healthy 
subjects and 
patients with DM 
Iontophoresis 
 
Healthy subjects: vasodilatation;  
Patients: constriction of forearm 
microcirculation 
[15] 
 
 
Table 1 Renovascular responses to hU-II in vitro. 
Species Vascular tissue  Response to hU-II Reference 
Rat Renal arteries 
 
 
Small renal arteries 
 
 
Unresponsive 
 
 
Endothelium-dependent 
vasodilatation;NO-release from intact 
endothelium 
[3,11,12] 
Mouse Renal arteries Unresponsive [13] 
Dog Renal arteries Unresponsive [13] 
Pig Renal arteries Unresponsive [13,14] 
Monkey Renal arteries Vasoconstriction [13] 
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U-II in renal and metabolic disease 
Renal disease 
Levels of pre-pro U-II mRNA expression in kidney vary considerably between studies. In 
rat and mouse kidney hardly any U-II was detected [16], while sheep exhibited renal 
production of U-II [17]. Also in human kidney the amount of U-II expressed varied 
[11,18-20]. The cause of disparity in expression levels between studies is unknown, but 
may be related to differential regulation between subjects.  
In humans, U-II was found in distal and proximal convoluted tubules, glomeruli, 
collecting tubules and collecting ducts, and in endothelial cells in renal arteries [21]. UT 
mRNA is mainly expressed in the renal cortex [19,22]. In renal biopsy tissue of patients 
with diabetic nephropathy U-II and UT mRNA were increased by 45 to 2000-fold when 
compared to normal subjects [23], suggesting a role of U-II in the progression of renal 
disease. This is in line with data by Totsune et al. who showed that, compared to 
healthy subjects, circulating levels of U-II-like immunoreactivity were 2- and 3- fold 
higher in patients with renal dysfunction not on dialysis and patients with renal 
dysfunction on dialysis, respectively [20]. In this study plasma and urinary U-II levels 
were also increased in diabetic patients with renal dysfunction when compared to 
diabetics with normal renal function. In patients with hypertensive renal disease urinary 
U-II-like immunoreactivity was higher compared to normotensive renal disease patients, 
which may be the result of hypertensive target organ damage [19]. 
Children with minimal change nephrotic syndrome (MCNS) showed decreased plasma 
U-II  and increased urinary U-II during relapse. No relationship between U-II and clinical 
and/or laboratory parameters could be established. Thus, although changes in plasma 
and urine U-II were observed during relapse, this may be the result of marked 
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proteinuria rather than reflecting a role in mediating the clinical and laboratory 
manifestations in children [24]. 
U-II is altered in patients with end-stage renal disease (ESRD). Interestingly, an inverse 
correlation to risk was observed. While plasma U-II levels were elevated in ESRD 
compared to healthy controls, patients had reduced endothelial activation and levels of 
biomarkers of atherosclerosis were decreased [25,26]. Also, a more favorable 
echocardiographic profile and a lower overall cardiovascular risk were observed [27]. 
These findings would point toward a protective role of U-II in some forms of renal 
disease through interference of U-II with sympathetic and NO systems [28]. 
Metabolic syndrome and Type 2 DM 
In addition to its effect on blood pressure, U-II may contribute to progression of 
metabolic syndrome and Type 2 DM through other pathways.  
A neurohormonal role affecting insulin secretion has been suggested based on several 
observations. UT is expressed in human liver and pancreas [29,30]. In perfused rat 
pancreas, infusion of U-II inhibited glucose-induced insulin secretion, not affecting 
glucagon, somatostatin, and basal insulin secretion [31-33]. Sheep displayed 
hyperglycemia after infusion of U-II, suggesting a central effect of U-II leading to 
increases in epinephrine and cortisol levels [4], which trigger increased insulin 
secretion. U-II and UT receptor in tubular epithelial cells may play a role in activation of 
vasoactive hormone, injurous cytokines, and extracellular matrix proteins in the diabetic 
state [34]. 
Diabetic mice exhibit higher concentrations of U-II and UT mRNAs in skeletal muscle 
[35]. In streptozotocin-induced diabetic rats, expression of U-II and UT was significantly 
upregulated at both mRNA and protein levels in the diabetic kidneys compared with 
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controls. The upregulated expressions of U-II and UT in the kidney were accompanied 
by significantly increased renal TGF1 expression, renal extracellular matrix (fibronectin 
and collagen IV) accumulation, and renal dysfunctions [36]. In human diabetic patients 
plasma levels of U-II are elevated irrespective of the presence or absence of 
proteinuria. The elevation is independent of fasting plasma glucose or blood 
glycosylated hemoglobin (HbA1C) level, suggesting that the production or release of U-II 
is not due to hyperglycemia [9,30,37]. The role of U-II is further suggested based on 
findings by Ong et al. It was observed that the region 1p36 in human chromosome 1 
contained a locus which is associated with a higher susceptibility to developing DM2 in 
Chinese and Japanese [9]. The exact disease-containing gene in this locus is unknown, 
but the gene encoding U-II is located at 1p36 and may be one of the candidate genes. 
Further, the UT receptor has been suggested to play a role in the development of 
impaired glucose tolerance (IGT), a prediabetic condition. However, these association 
studies do not prove causation and no data have been generated in other populations, 
such as Caucasians [9]. 
The urotensin-II receptor antagonist palosuran 
Palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-
quinolin-4-yl)-urea sulfate salt) is a potent and specific antagonist of the human UT 
receptor (Figure 1). In in vitro binding assays, palosuran demonstrated selective binding 
and competitive mode of antagonism on the human UT receptor [38]. In vivo, palosuran 
prevented the no-reflow phenomenon after renal artery clamping in rats, without a 
decrease in blood pressure. Subsequent development of acute renal failure and the 
histological consequences of ischemia could be prevented in this model [38].  
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In a rat model of diabetes, palosuran was able to improve the pancreatic and renal 
function [39]. In this accelerated model, rats were injected with streptozotocin and 
underwent unilateral nephrectomy, without administration of insulin. The administration 
of streptozotocin destroyed pancreatic  cells, leading to insulin-sensitive 
hyperglycemia, and associated complications, including nephropathy [39]. After chronic 
treatment with palosuran for 25 weeks, more than double the numbers of diabetic rats 
survived, when compared to untreated rats. During treatment with palosuran for 16 
weeks, the drug prevented a further increase in glycemia, as well as an increase in 
triglycerides and decreased serum cholesterol when compared to untreated diabetic 
rats. HbA1C concentrations markedly increased in the untreated diabetic rats and slightly 
but significantly reduced in the diabetic rats treated with palosuran. Histopathology of 
the pancreas at the end of the 16-week treatment period showed that diabetic rats had 
smaller and fewer -cells than non-diabetic rats. While rats treated with palosuran still 
had a decreased number of -cells, the cells were larger when compared to untreated 
diabetic rats. Further, albuminuria and renal damage was assessed in this model. While 
Figure 1 Chemical structure of palosuran sulphate salt. 
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albuminuria increased rapidly with time in the untreated diabetic rats, palosuran could 
attenuate, but not normalize, the albuminuria. Palosuran had no significant effect on 
renal vascular resistance, but significantly increased renal plasma flow and glomerular 
filtration rate. It was suggested by the histopathology that palosuran decreased 
incidence and severity of renal lesions (tubular degeneration/regeneration, tubular 
vacuolation, glomerulosclerosis) in diabetic rats [39]. 
Summary and conclusion 
Besides a prominent role of U-II as the most potent vasoconstrictor known to date, U-II 
and its receptor may also play a prominent role in the development of renal and 
metabolic diseases, such as Type 2 DM. Indeed, in kidney tissue of mice, rats, and 
humans, U-II and its receptor have been identified and increased levels of U-II and UT 
receptor have been observed in patients with renal dysfunction and diabetes. Apart from 
its renovascular effect, it is suggested that U-II has a hypo-osmotic and neurohormonal 
function, which, when disrupted, can contribute to progression of renal and metabolic 
disease.  
In a rat model of diabetes, treatment with the UT receptor antagonist palosuran 
improved survival, increased insulin levels and slowed its release in glycemia, HbA1C 
and serum lipids. Furthermore, palosuran increased renal blood flow and delayed the 
development of proteinuria and renal damage.  
Thus, UT receptor antagonists may constitute a new class of treatments for renal and 
metabolic diseases. It is therefore of importance to explore the potential of UT receptor 
antagonists in humans. 
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Abstract 
Palosuran is a new potent and specific antagonist of the human urotensin II (U-II) 
receptor (UT receptor). This entry-into-human study evaluated the tolerability and 
safety, pharmacokinetics, and pharmacodynamics of palosuran in a double-blind, 
placebo-controlled, single ascending-dose design. Oral doses of 5 to 2000 mg were 
given to 9 sequential groups of 8 healthy young men (6 on active drug, 2 on placebo) 
each. At regular intervals, tolerability and safety parameters, and plasma levels of 
palosuran and U-II were determined. Urine was collected to determine excretion of 
sodium, potassium, creatinine, and palosuran. 
In this study, palosuran was well tolerated. No serious adverse events or dose-related 
adverse events were reported. No treatment-related pattern was detected for vital signs, 
clinical laboratory parameters, or electrocardiography parameters. After rapid 
absorption, palosuran displayed a plasma concentration-time profile characterized by 2 
peaks at approximately 1 and 4 hours after drug administration. The apparent terminal 
elimination half-life was approximately 20 hours. AUC and Cmax values increased 
proportionally with doses up to 500 mg. Excretion of unchanged palosuran in urine was 
limited. No consistent effect was found on any of the pharmacodynamic variables 
measured. 
The results of this entry-into-humans study warrant further investigation of the 
therapeutic potential of palosuran. 
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Introduction 
Urotensin-II (U-II), a cyclic undecapeptide, was first characterized from the urophysis 
(terminal organ of the caudal neurosecretory system in teleost fish) in the 1960s [1,2]. 
Identified to have haemodynamic, gastrointestinal, reproductive, osmoregulatory, and 
metabolic functions in fish [2-4], the relevance of U-II for human physiology was 
unknown as it was believed that this peptide was exclusively present in lower 
organisms. The successive identification of U-II in mammals like rats, pigs, monkeys, 
and humans [4-6] and its receptor, the orphan G-protein coupled receptor 14, which 
was renamed as the urotensin-II receptor (UT receptor) [4,7,8] led to a renewed interest 
in this neurohormonal system. Through binding to the UT receptor, which in humans is 
mainly found in the heart and arterial vessels, U-II activates the inositol triphosphate 
system leading to the release of intracellular calcium [3,9]. U-II has been described as 
the most potent vasoconstrictor to date, being up to 2 orders of magnitude more potent 
than endothelin-1 (ET-1) [6,8-11]. However, its function as a cardiovascular mediator is 
not fully understood; the response to U-II varies considerably between species, between 
vascular beds, and even between individual vessels of the same type [3,4,9,12-14]. 
Although less present than in the heart and arterial vessels, UT-receptors are also 
abundantly expressed in the epithelial cells of the renal tubules and, compared to other 
organs, high concentrations of U-II have been observed in endothelial cells of the renal 
vasculature. In this context, U-II could play a role in regulating the glomerular filtration 
rate by paracrine or endocrine action [5,15]. 
Though U-II is mostly described as a vasoconstrictor, it has also been reported that U-II 
elicits no or even vasodilating effects [14,16,17]. U-II circulates in the blood of healthy 
subjects and its concentrations are increased in patients with hypertension, renal 
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dysfuntion, diabetes, atherosclerosis, and congestive heart failure [18-25]. These 
observations provide a rationale to study an UT-receptor antagonist in the treatment of 
these diseases. 
Palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-
quinolin-4-yl)-urea sulfate salt) is a non-peptidic, orally active, potent, selective, and 
competitive antagonist of the human UT receptor [26]. It was synthesized in the course 
of a chemical optimization effort of UT receptor antagonists identified by random 
screening of the Actelion compound collection using radioligand binding techniques 
[26]. In rat models of acute renal failure and diabetes, palosuran significantly improved 
renal function, decreased the number of tubular and tubulointerstitial lesions, and 
improved survival [26,27]. This report describes the entry-into-humans study with the 
first UT-receptor antagonist known to enter clinical trials. We describe the safety and 
tolerability, pharmacokinetics, and pharmacodynamics of palosuran given as single oral 
doses in healthy male subjects. 
Methods 
Study subjects 
After written informed consent was obtained, 76 healthy male volunteers participated in 
this study, which was approved by the Ethics Committee of Baden-Württemberg, 
Stuttgart, Germany. Subjects (age range 21-50 years) were in good health, were not 
taking any prescription or nonprescription medication, did not smoke, had a body mass 
index (BMI) between 20 and 27 kg/m2, and had values for vital signs, ECG parameters, 
and clinical laboratory parameters that were either within the normal range or did not 
deviate to a clinically relevant extent from normal. 
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Study design 
This study was designed as a single-center, double-blind, randomized, placebo-
controlled, ascending single-dose study. After screening, 9 successive groups of 8 
subjects each received a single oral dose of palosuran. In each group, 6 subjects 
received a dose of 5, 10, 25, 50, 125, 250, 500, 1000, or 2000 mg palosuran and 2 
received matching placebo, all given as capsule formulations. Based on in vivo 
exposure data in animals a starting dose of 5 mg was chosen, which was 1000- and 
2000-fold lower than the no-observed-adverse-effect-level in dogs and rats, 
respectively. Although there is a marked difference in affinity of palosuran to human 
versus rat receptors, this dose would still constitute a sufficiently large safety margin. 
After each dose group, the tolerability and safety was evaluated to decide whether the 
next higher dose group could proceed. 
Safety and tolerability parameters were assessed regularly throughout the study. 
Subjects were in the clinic from 25 hours before until 36 hours following intake of study 
drug, during which time blood and urine samples were collected for assessment of 
pharmacokinetic and pharmacodynamic parameters. In the 5 days preceding the in-
clinic period, subjects were requested to refrain from eating foods with particularly high 
sodium and potassium content. During the in-clinic period, the daily intake of sodium 
(Na) and potassium (K) was kept at about 120 mEq and 60 mEq, respectively. In 
addition, the intake of water on days -1 and 1 was standardized. An end-of-study 
examination was performed three to four days after study drug intake. 
Safety and tolerability assessments 
All adverse events (AE) that occurred after drug administration and up to the end-of-
study examination were recorded together with the seriousness, severity, time of onset, 
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duration, and relationship to the treatment. A physical examination was performed at 
screening and at the end-of-study visit. Vital signs (supine and standing diastolic and 
systolic blood pressure and pulse rate) were measured at screening; 12 and 24 hours 
before drug intake; immediately prior to and 1, 2, 4, 8, 12, 16, 24, 36 hours after drug 
administration, and at the end-of-study visit. A 12-lead ECG was recorded at screening; 
24 hours before drug intake (day -1); immediately prior to and 1, 4, 8, 24, and 36 hours 
after drug administration; and at the end-of-study visit. Besides heart rate, QRS, PQ/PR, 
and QT and QTc intervals were measured. In addition, the ECGs were checked by the 
investigator and any abnormalities in ECG morphology were recorded. Laboratory test 
parameters were assessed at screening, 24 hours before drug intake, 24 hours after 
drug administration (day 2), and at the end-of-study visit. 
Pharmacokinetic and pharmacodynamic sampling 
For determination of palosuran and U-II, venous blood samples (9 ml) were collected 
24, 20, 16, and 12 hours before, immediately prior to and 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 
8, 10, 12, 16, 24, 30, and 36 hours after study drug intake in tubes containing EDTA as 
anticoagulant. Following centrifugation at 1500 g for 10 minutes at 4 ºC, plasma was 
separated and divided over two tubes (one for palosuran and one for U-II determination) 
and frozen at -20 ºC until assayed. For determination of palosuran, urinary electrolytes 
(Na and K), and creatinine, urine was collected on day -1 over 3 intervals of 4 hours, 
followed by one interval of 12 hours. On day 1, urine was collected during 3 intervals of 
4 hours, followed by 2 intervals of 12 hours. From the urine collected during each 
interval the volume was determined, a sample of 5 ml was taken, and stored at -20 ºC 
until assayed. 
 
Part II: Clinical Pharmacology of palosuran  
            in healthy subjects  
Chapter 3.  Single-dose PK, PD, and safety of palosuran   
 
59 
Bioanalytical methods 
For determination of palosuran in plasma and urine, to each 100 µl sample 200 µl of a 
50/50 mixture of acetonitril/ethanol spiked with a concentration of 80 ng/ml internal 
standard were added. The samples were vortexed and centrifugated and 50 µl of the 
supernatant were diluted with 300 µl of water containing 0.3% formic acid. Of this 
diluted sample 20 µl were transferred to autosampler vials. Plasma and urine 
concentrations of palosuran were determined using a validated liquid chromatography 
coupled to tandem mass spectrometry assay operating in the positive ionization 
detection mode. The limit of quantification (LOQ) was 1.0 ng/ml (between-run 
coefficients of variation were below 8.0% and 8.7% and intra-day inaccuracies were 
below 2.5 % and 7.5% for plasma and urine, respectively). The assay was validated in 
the concentration range 1 - 2000 ng/ml for both plasma and urine. U-II was determined 
using a RIA method developed in-house at Actelion Pharmaceuticals Ltd. The LOQ was 
0.4 - 0.5 pg/ml. Urinary creatinine was determined using an adaptation of the method 
described by Bartels et al. [28] and urinary Na and K were determined by standard 
methods of flame photometry using an Eppendorf Flame Photometer, Eppendorf AG, 
Hamburg, Germany, Model FCM 6341.  
Data analysis 
Safety and tolerability parameters were analyzed descriptively. Subjects treated with 
placebo in the different treatment groups were pooled for analysis of safety. Calculation 
of model-independent pharmacokinetic parameters for palosuran was performed using 
Professional WinNonlin Version 4.0.1. (Pharsight Corp., Mountain View, California, 
USA). The maximum observed plasma concentration (Cmax) and the time to the 
occurrence of Cmax (tmax) were obtained directly from the plasma concentration-time 
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curves. The area under the plasma concentration-time curve to the last sample time 
with a concentration above the LOQ (AUC0-t) was obtained by the linear trapezoidal 
rule. The area under the plasma concentration-time curve extrapolated to infinity (AUC0-
∞) was calculated by combining AUC0-t and AUCextra. The AUCextra represents an 
extrapolated value obtained by Ct/λz, where Ct is the last plasma concentration 
measured above the LOQ and λz is the first order rate constant associated with the 
terminal log-linear portion of the plasma concentration-time curve. The t1/2 was obtained 
by dividing ln2 by λz. From the palosuran urine concentrations, the percentage of total 
dose excreted in urine and the renal clearance (CLR) were calculated. CLR was 
calculated by dividing the total amount of unchanged drug excreted during 36 hours 
after study drug intake by AUC0-36. 24-Hour urinary creatinine, and Na and K excretion 
data corrected for creatinine were analyzed descriptively.  
Statistical analysis 
Dose-proportionality of palosuran was explored by comparing Cmax and AUC values, 
corrected for dose and log transformed, using a power model described by Gough et al. 
[29]. All analyses were performed first including all doses above 25 mg, and then 
repeated after sequentially excluding the 2000 and 1000 mg groups. Plasma 
concentrations of the 5- and 10-mg dose groups could not be determined. In addition, 
as most of the plasma concentrations of the 25-mg group were close to LOQ, the 
pharmacokinetics of this group could not be well characterized. Further, dose-
normalized values for AUC were plotted and subjected to linear regression. 
Results 
Four subjects, before taking any study medication, reported nausea and vomiting on 
day -1. As this could have affected their electrolyte balance, they were taken out of the 
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study and were replaced. As the subjects were withdrawn before study drug intake, they 
were not included in the analysis of safety, pharmacokinetics, and pharmacodynamics. 
All other 72 subjects were compliant with the selection criteria and completed the study 
according to the protocol. The demographics were similar for all dose groups studied.  
No serious adverse events were reported in this study. A summary of the adverse 
events reported more than once during the study including those AEs judged to be 
unrelated to study treatment is provided in Table 1. AEs that were reported more than 
once by the same subject were counted only once in this Table.  
 
Of the 54 subjects treated with palosuran, 20 reported a total of 51 AEs (17, 20, and 14 
were of mild, moderate and severe intensity, respectively). Of the 18 subjects treated 
with placebo, 3 reported a total of 5 AEs (4 and 1 were of mild and moderate intensity, 
Table 1 Summary of AEs reported more than once during the study 
(treatment emergent and including unrelated) by frequency. 
 Treatment 
 5 mg 10 mg 25 mg 50 mg 125 mg 250 mg 500 mg 1000 mg 2000 mg Placebo 
N 6 6 6 6 6 6 6 6 6 18 
Number of subjects with at  
least 1 AE 3 1 1 3 - 2 2 4 4 3 
Total number of AEs 4 2 1 6 - 2 2 4 4 3 
Most common adverse events           
Headache  1 - - 1 - 1 1 - 1 3 
Dizziness  1 1 1 1 - - - 3 - - 
Nausea - - - - - - - 1 2 - 
Vomiting  - - - - - - - - 2 - 
Pallor - - - - - - - 2 - - 
Fatigue - - - 1 - - - - 1 - 
Postural hypotension - - - - - - - 2 - - 
 
AEs reported more than once by the same subject are counted only once 
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respectively). All AEs resolved spontaneously, except for eight subjects, who required 
treatment for headache with an analgesic (paracetamol), and 1 subject, who was 
treated for diarrhoea and vomiting. All AEs resolved without sequelae. The most 
frequently reported AEs were headache, dizziness, and sweating (Table 1). No dose-
relationship could be discerned for any AE. No treatment-related pattern could be 
detected for vital signs, clinical laboratory test parameters, and ECG parameters.  
The mean plasma concentration-time curves for palosuran are shown in Figure 1. In the 
dose groups that received 25 mg or less, most samples were below the LOQ, and were, 
therefore, not included in the analysis. The plasma concentration-time curve of 
palosuran was characterized by two absorption peaks at approximately 1 and 4 hours 
following administration. This double-peak phenomenon was less pronounced in the 
higher dose groups. The disposition of palosuran was characterized by an apparent 
elimination half-life of approximately 20 hours. A summary of the pharmacokinetic 
parameters is presented in Table 2. A graphical presentation of exploration for dose-
proportionality of the pharmacokinetics of palosuran is shown in Figure 2. The 
pharmacokinetics were not dose-proportional over the entire dose range tested, as 
explored with the power model described by Gough et al. However, results from the 
statistical analysis showed that up to and including a single dose of 500 mg AUC0-∞ and 
Cmax were dose-proportional. Table 3 summarizes the pharmacokinetic parameters of 
palosuran in urine. Urinary excretion of unchanged palosuran did not exceed 5% of the 
administered dose. Urinary excretion of unchanged palosuran and CLR tended to 
increase with increasing dose.  
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Most plasma samples had U-II concentrations below or just above the LOQ. No 
observations were made suggesting that palosuran affected U-II plasma levels. The 
volume and the creatinine level of the collected urine on day –1 and 1 were similar (data 
 
not shown). In all treatment groups (including placebo), Na and K tended to decrease in 
the 4-8 hour and 8-12 hour intervals (data not shown) when comparing day 1 to -1. A 
graphical presentation of the 24-hour excretion data of Na and K after correction for 
creatinine is shown in Figure 3. No effect of palosuran could be discerned for any of the 
urinary excretion parameters.  
Figure 1 Mean plasma concentration versus time profiles of palosuran in 
healthy subjects (n = 6 per group) on a semi-logarithmic scale.  
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Treatments were a single dose of 50 mg (), 125 mg (), 250 mg (), 500 mg (), 1000 mg (), and 2000 mg (). 
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Discussion 
The U-II / UT receptor system has only recently been discovered in humans and its role 
is up to date poorly understood. As increased plasma levels of U-II and/or upregulation 
of the UT-receptor have been observed in diseases such as hypertension, heart failure,  
 
and diabetes, UT-receptor antagonists may have a potential to be beneficial in the 
treatment of these diseases. 
To our knowledge, this is the first study in which a U-II receptor antagonist was 
administered to human subjects. In this study we observed that palosuran was well 
tolerated up to and including a single dose of 2000 mg. Further, no treatment-related 
effects on clinical laboratory and ECG parameters could be discerned. Although U-II is 
considered to be a potent vasoconstrictor and could play a role in diseases such as 
hypertension, no effect on vital signs was observed in this group of healthy subjects.  
 
Figure 2 Dose-normalized values for AUC0-∞ and Cmax (arithmetic mean) of 
palosuran and results from linear regression (with 95% CI). 
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Figure 3 24-hour urinary excretion results (arithmetic mean and SEM) of 
sodium (left) and potassium (right) on day -1 () and 1 () (n = 6 
for each palosuran dose; n = 18 for placebo). 
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Table 2 Plasma pharmacokinetic parameters of single-dose palosuran in 
healthy subjects. 
 Treatment Cmax (ng/ml) tmax (h) AUC0- (ng.h/ml) t1/2 (h) 
50 mg 40.9 (25.5, 65.5) 2.0 (0.7 - 5.0)  246 (163, 370) 19.7 (10.3, 37.7) 
125 mg 144 (79.6, 260) 1.5 (0.3 - 3.0) 534 (308, 927) 22.8 (18.4, 28.2) 
250 mg 273 (217, 343) 0.7 (0.7 - 1.5) 1150 (795, 1665) 23.1 (16.3, 32.8) 
500 mg 455 (289, 715) 1.5 (0.7 - 4.0)    2306 (1927, 2758) 20.1 (16.9, 23.9) 
1000 mg  2015 (1180, 3442) 1.0 (0.3 - 1.0)     7671 (4570, 12876) 20.9 (17.3, 25.2) 
2000 mg  3373 (1890, 6018) 3.0 (1.5 - 4.0)     17446 (10403, 29256) 14.5 (10.2, 20.6) 
 
 
Data are geometric means (95% CI); for tmax data are median (range). 
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Indeed, in vitro experiments showed that U-II causes vasoconstriction in isolated 
coronary arteries and perfused hearts, but the magnitude of the effect considerably 
differs between species [30,31]. In humans mixed effects have been observed. In a 
study performed by Wilkinson et al. in which healthy subjects received intra-arterial 
human U-II, no response in any haemodynamic measure was observed despite a near 
30-fold increase in plasma concentrations of U-II [32]. In contrast, Böhm et al. 
demonstrated in an almost identical setting that U-II evoked potent vasoconstriction 
[33]. Some reports have suggested that the cardiovascular effects of U-II are mainly 
centrally induced [31,34,35]. Others have linked the effects of U-II to settings where 
endothelial cell function is comprised [36], which could be a reason why no effects can 
be observed in a healthy population. Also, effects have been attributed to direct 
activation of UT-receptors, especially in circumstances in which the UT-receptor system 
is upregulated [4,6,37]. Indeed, a difference in density of UT-receptors in the vessels 
resulted in a difference in efficacy of U-II. Usually the efficacy of U-II is found to be lower 
than that of other vasoconstrictors such as endothelin-1, angiotensin II, and 
Table 3 Urine pharmacokinetic parameters of single-dose palosuran in 
healthy subjects. 
 
Treatment 
% dose excreted  
unchanged in urine 
CLR (ml/min) 
50 mg 0.85 (0.58, 1.23) 36.1 (19.4, 67.0) 
125 mg 1.7 (0.96, 2.9) 79.3 (64.8, 96.9) 
250 mg 1.4 (0.91, 2.1) 60.8 (49.0, 75.5) 
500 mg 1.7 (1.1, 2.5) 69.5 (52.3, 92.3) 
1000 mg 4.1 (2.2, 7.4) 99.6 (88.0, 113) 
2000 mg 4.5 (2.7, 7.6) 95.3 (83.1, 109) 
  
   Data are geometric means (95% CI). 
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noradrenaline. Therefore, it is important to investigate whether U-II contributes to 
elevated blood pressure, and whether antagonism of the UT-receptor may provide an 
adequate therapy [36]. 
Palosuran was rapidly absorbed. The plasma concentration-time curve is characterized 
by a double-peak phenomenon, which could be related to enterohepatic recycling. The 
apparent terminal elimination half-life was approximately 20 hours, but in most subjects 
low palosuran plasma concentrations were measured after 12 hours. Based on this 
pharmacokinetic profile a twice-daily dosing regimen would be appropriate for further 
studies. The pharmacokinetics were dose proportional up to and including a single dose 
of 500 mg. At higher doses a more than dose proportional increase was observed 
together with an increase in renal excretion of unchanged palosuran, though the latter 
was still below 5% of the total dose administered. Several studies suggested the ability 
of U-II to regulate transepithelial transport of ions and water across a variety of 
osmoregulatory surfaces in teleost fist [38]. A role on the renal physiology is also 
suggested for mammals based on the detection of mRNA transcripts for U-II and UT 
receptors in human kidneys [15,39]. As U-II is produced in the kidney [40] it might have 
a significant contribution to renal disease. It was hypothesized that antagonism of the U-
II/UT receptor system by the UT receptor antagonist palosuran could affect the 
excretion of urinary electrolytes and creatinine extreation, and, for this reason, these 
variables were assessed in this study to serve as potential pharmacodynamic markers. 
As it is unknown how the production of U-II is regulated, plasma levels of U-II were 
measured in this healthy subject to gain more understanding of the effects of 
antagonism of the U-II system. No pharmacodynamic markers (were identified that 
could guide dose selection for further clinical studies in patients. Indeed, in patients with 
diabetes and diabetic nephropathy, increased plasma levels of U-II and increased 
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expression of UT-receptors have been observed [21,23]. However, no effects on Na, K 
or creatinine excretion in urine were found in this healthy subjects study. As previously 
mentioned, the effects of U-II might be dependent on the state of the endothelium of the 
vessel. In healthy subjects, the endothelium-derived nitric oxide function is intact, which 
could explain why no effects of antagonism of UT-receptors were seen. Alternatively, 
the treatment duration, i.e., a single dose, might have been too short to observe an 
effect. Clozel et al. have shown in pathological rat models that palosuran improved 
blood flow after renal ischaemia, preserved renal function in renal failure models, and 
increased survival in diabetic models, without having an effect on blood pressure [27]. 
The improved survival results from a multitude of factors attributed to palosuran 
treatment. Palosuran increased insulin and slowed the increase in glycemia, 
glycosylated hemoglobin, and serum lipids. Furthermore, palosuran increased renal 
blood flow and delayed the development of proteinuria and renal damage.[27] As in 
healthy subjects glucose production is well regulated, the use of pharmacodynamic 
parameters from the rat model was limited. 
More insight in the function of U-II in patients with diabetes and renal impairment is 
needed. Thus far, due to the lack of UT-receptor antagonists, the role of the U-II/UT 
receptor system in disease has not been fully characterized [30]. With the development 
of the selective, potent, U-II receptor antagonist palosuran, it will be possible to 
investigate the role of U-II in disease more clearly. 
In conclusion, though its clinical usefulness has not yet been established in humans, the 
tolerability and pharmacokinetic profile of palosuran warrant further studies in patients to 
further investigate and understand the potential role of UT receptor antagonists in 
different diseases. 
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Abstract 
Purpose: To investigate the multiple-dose pharmacokinetics, pharmacodynamics, 
tolerability, and safety of palosuran, a selective, potent antagonist of the human 
urotensin-II receptor. 
Methods: This was a double-blind, randomized, placebo-controlled study. Three 
sequential groups were treated with 25, 125, and 500 mg palosuran b.i.d. or placebo for 
6.5 days.  
Results: The plasma concentration-time profile was characterized by rapid absorption 
and peaks at 1 and 4 h after drug administration. Steady-state conditions were reached 
after 4 to 5 days of dosing. The apparent terminal half-life was approximately 25 h. The 
accumulation factor was approximately 2.5. With increasing dose, a more than dose 
proportional increase in AUCτ and Cmax was observed. Urinary excretion of unchanged 
palosuran was less than 3% of the administered dose. No consistent effect was found 
on any of the investigated pharmacodynamic parameters. Palosuran was well tolerated 
in multiple doses up to 500 mg b.i.d.   
Conclusion: Palosuran has a favorable pharmacokinetic, tolerability, and safety profile 
that warrants further investigations in humans. 
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Introduction 
The discovery of urotensin-II (U-II), a cyclic undecapeptide, in the urophysis (terminal 
organ of the caudal neurosecretory system) in teleost fish dates from the 1960s [1,2]. 
Initially believed to be only present in lower organisms, the subsequent identification in 
mammals of U-II and the U-II receptor (UT receptor, originally named the G-protein 
coupled receptor 14) [3-5], led to a renewed interest in this neurohormonal system [5-
7]. U-II has been described as a vasoconstrictor, with a potency even larger than that 
of endothelin-1 (ET-1) [4,8,9]. Currently, the precise function of U-II is not fully 
understood, and responses to U-II are found to vary between species, vascular beds, 
as well as individual vessels of the same type [5,8,10-14]. Several reports have shown 
that there are differences in U-II plasma levels or UT-receptor expression between 
healthy subjects and patients with hypertension, renal dysfunction, diabetes, 
atherosclerosis, or congestive heart failure [15-22], suggesting that elevated plasma 
levels of U-II are associated with a detrimental effect in such diseases. On the basis of 
these findings, the development of an antagonist of the UT receptor to block such 
effects would possibly present a new approach. 
Palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-
quinolin-4-yl)-urea sulfate salt) is a non-peptidic, orally active, potent, selective, and 
competitive antagonist of the human UT receptor [23]. In rat models of acute renal 
failure and diabetes, palosuran significantly improved renal function, decreased the 
number of tubular and tubulointerstitial lesions, and improved survival [23,24]. In the 
entry-into-humans study, it was shown that palosuran exhibited a good safety profile 
and was well tolerated up to a single dose of 2000 mg (no higher dose was tested) 
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[25]. Excretion of palosuran in urine was found to be limited [25]. In addition, no 
pharmacodynamic markers (plasma levels of U-II, urinary excretion parameters) could 
be identified after single dosing that could guide further dosing considerations [25]. In 
this report, we describe the pharmacokinetics, pharmacodynamics, tolerability, and 
safety of palosuran administered as multiple doses to healthy male subjects. 
Methods 
Study subjects 
After approval of the study by the Ethics Committee of Baden-Württemberg, Stuttgart, 
Germany, 24 healthy male subjects were recruited. All subjects (age range 22-48 
years) signed the informed consent and completed the study. At screening, the 
subjects were in good health, did not take any prescription or nonprescription 
medication, did not smoke, had a body mass index (BMI) between 19.6 and 28.0 
kg/m2, and had values for vital signs (heart rate [HR], systolic blood pressure [SBP], 
and diastolic blood pressure [DBP]), ECG, and clinical laboratory parameters either 
within the normal range or not deviating to a clinically relevant extent from normal. 
Study design 
This study was designed as a single-center, double-blind, randomized, placebo-
controlled, ascending multiple-dose study. After screening, 3 successive groups of 8 
subjects (6 on palosuran and 2 on matching placebo) each received multiple doses of 
palosuran b.i.d. for 6.5 days. A relatively wide dose range of 25, 125, and 500 mg 
palosuran, administered orally in capsules, was chosen to enable the initiation of 
clinical studies in patients at varying doses. Based on the pharmacokinetic profile of 
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palosuran in the entry-into-humans study, b.i.d. dosing was considered to be the most 
appropriate dosing regimen [25].  
After each dose group, the tolerability and safety was evaluated to decide whether the 
next higher dose group could start. Tolerability and safety parameters were assessed 
regularly throughout the study. Subjects were in the clinic from approximately 24 h 
before the first drug intake until 36 h after the last study drug intake, during which time 
blood and urine samples were collected for assessment of pharmacokinetic and 
pharmacodynamic parameters. An end-of-study examination was performed 2 to 4 
days after last study drug intake. In the 5 days preceding the in-clinic period, subjects 
were requested to refrain from eating foods with particularly high sodium and 
potassium content. During the in-clinic period, the daily intake of sodium (Na) and 
potassium (K) was kept at about 120 mEq and 60 mEq, respectively. The timing and 
composition of meals was standardized for all subjects throughout the in-clinic period. 
During the days of pharmacokinetic profiling, i.e., Days 1 and 7, the meals were 
identical for all subjects. Products containing grapefruit were forbidden from screening 
until the end-of-study examination. 
Pharmacokinetic and pharmacodynamic sampling 
For determination of palosuran and U-II, venous blood samples (9 ml) were collected 
at 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 h after the morning study drug intake 
on Day 1 and 7 and immediately prior to each study drug intake from Days 1 to 7. 
Samples were collected in tubes containing EDTA as anticoagulant. Following 
centrifugation at 1500 g for 10 min at 4 ºC, plasma was separated and divided over 
two tubes (one for palosuran and one for U-II determination) and frozen at -20 ºC until 
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assayed. For determination of palosuran, urinary electrolytes (Na and K), and 
creatinine, urine was collected on Day 1 and Day 7 over 3 intervals of 4 h. Of the urine 
collected during each interval the volume was determined, a sample of 5 ml was 
taken, and stored at -20 ºC until assayed. 
Bioanalytical methods 
For determination of palosuran in plasma and urine, to each 100 µl sample 200 µl of a 
50/50 mixture of acetonitril/ethanol spiked with a concentration of 80 ng/ml internal 
standard (deuterated analog) were added. The samples were vortexed and 
centrifugated and 50 µl of the supernatant were diluted with 300 µl of water containing 
0.3% formic acid. Of this diluted sample 20 µl were transferred to autosampler vials. 
Plasma and urine concentrations of palosuran were determined using a validated 
liquid chromatography coupled to tandem mass spectrometry assay operating in the 
positive ionization detection mode. The limit of quantification (LOQ) was 1.0 ng/ml and 
between-run coefficients of variation were below 12.0% and 10.0% with intra-day 
inaccuracies below 6.0 % and 2.5% for plasma and urine, respectively. The assay was 
validated in the concentration range 1 - 2000 ng/ml for both plasma and urine. U-II 
plasma concentrations were investigated in the 500 mg dose group using a RIA 
method developed in-house at Actelion Pharmaceuticals Ltd. The LOQ was 0.6 pg/ml. 
Urinary creatinine was determined using an adaptation of the method described by 
Bartels et al. [26] and urinary Na and K were determined by standard methods of 
flame photometry using an Eppendorf Flame Photometer (Eppendorf AG, Hamburg, 
Germany, Model FCM 6341).  
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Tolerability and safety assessments 
All adverse events (AE) that occurred after drug administration and up to the end-of-
study examination were recorded together with the seriousness, severity, time of 
onset, duration, and relationship to the treatment. A physical examination was 
performed at screening and at the end-of-study visit. Vital signs (supine and standing 
SBP, DBP, and HR) were measured at screening; 24 h before drug intake; 
immediately prior to and 1, 2, 4, 8, 12 h after morning drug administration on Day 1, 4 
h after evening administration on Day 1; immediately before and 4 h after each dose 
administration on Days 2-6; immediately prior to and 1, 2, 4, 8, 12, 24, 36 h after 
morning drug administration on Day 7; and at the end-of-study visit. A 12-lead ECG 
was recorded at screening; immediately prior to and 1, 4, 8, 12 h after morning drug 
administration on Day 1; immediately before and 4 h after each dose administration on 
Days 3 and 5, immediately prior to and 1, 4, 8, 12, 24 h after morning drug 
administration on Day 7; and at the end-of-study visit. Besides heart rate, QRS, 
PQ/PR, QT, and QTc intervals were measured. Laboratory test parameters were 
assessed at screening, 24 h before drug intake, immediately prior to the morning dose 
administration of day 4, 24 h after the morning drug administration on Day 7, and at 
the end-of-study visit. 
Data analysis 
Tolerability and safety parameters were analyzed descriptively. For this, subjects 
treated with placebo in the different treatment groups were pooled. Calculation of 
model-independent pharmacokinetic parameters of palosuran was performed using 
Professional WinNonlin Version 4.0.1. (Pharsight Corp., Mountain View, California, 
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USA). The maximum observed plasma concentration (Cmax) and the time to the 
occurrence of Cmax (tmax) were obtained directly from the plasma concentration-time 
curves. The area under the plasma concentration-time curve during one dosing 
interval (AUCτ) was calculated according to the linear trapezoidal rule using the 
measured concentration-time values above the LOQ during one dosing interval. The 
t1/2 was obtained by dividing ln2 by λz. Trough levels of palosuran were used to assess 
the attainment of steady-state conditions. The accumulation index was calculated by 
dividing AUCτ on Day 7 by AUCτ on Day 1. From the palosuran urine concentrations, 
the percentage of total dose excreted unchanged in urine and the renal clearance 
(CLR) were calculated. CLR was calculated by dividing the total quantity of unchanged 
drug excreted during 12 h after study drug intake by AUCτ. 12-Hour urinary creatinine, 
and Na and K excretion data, corrected for creatinine to reduce the variability 
introduced by potential incomplete sampling, were analyzed descriptively.  
Statistical analysis 
Dose-proportionality of palosuran pharmacokinetics was explored by comparing Cmax 
and AUC values, corrected for dose and log transformed, using a power model 
described by Gough et al. [27]. Further, dose-normalized values for AUC were plotted 
and subjected to linear regression. Attainment of steady-state conditions was 
performed using graphical depictions. 
Results 
All 24 subjects were compliant with the selection criteria and completed the study 
according to the protocol. The demographics were similar for all dose groups studied.  
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No serious AEs were reported in this study. A summary of the AEs reported more than 
once during the study including those AEs judged to be unrelated to study treatment is 
provided in Table 1. AEs that were reported more than once by the same subject were 
counted only once in this Table. Of the 18 subjects treated with palosuran, 9 reported 
a total of 16 AEs. Of the 6 subjects treated with placebo, 1 reported a case of mild 
pruritis. Except for 1 case of moderate stye, which was treated with topical 
dexamethasone, dexpanthenol, and gentamicin preparations, all AEs reported during 
treatment with palosuran were of mild intensity. All AEs resolved without sequelae. 
The reporting of AEs was not concentrated on certain days of the study but appeared 
to be evenly distributed (data not shown). Abdominal distension, diarrhea, fatigue, 
loose stools, and procedural site reaction were reported by several subjects whereas 
all other AEs occurred only once. The total number of AEs increased with dose but no 
dose-relationship could be detected for any AE.  
No treatment-related pattern was detected to suggest an effect of palosuran on vital 
signs, clinical chemistry (including liver enzymes) or urinalysis parameters. No 
treatment-emergent ECG abnormalities were identified or reported by the investigator. 
There were no clinically significant changes in mean PQ, QT, and QTc intervals.  
The mean plasma concentration-time profile of palosuran, after administration of 125 
mg palosuran b.i.d., is shown in Figure 1. The mean plasma concentration-time 
profiles on Day 7 of palosuran for the different doses are shown in Figure 2. Palosuran 
was rapidly absorbed after dosing. Both after single- and multiple-dose administration, 
the plasma concentration-time profiles were characterized by two peaks at 
approximately 1 and 4 h after drug administration. 
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The disposition of palosuran on Day 7 was characterized by a biphasic elimination 
with an apparent elimination half-life that varied from 21.1 h to 29.9 h in the different 
dose groups. A summary of the pharmacokinetic parameters is presented in Table 2. 
Visual inspection of the trough concentrations indicated that steady-state conditions 
were reached after 4 to 5 days of dosing (Figure 1). The b.i.d. dosing regimen chosen 
in this study led to consistently greater AUC values on Day 7 when compared to Day 
1 (Table 2). The accumulation index varied from 1.9 to 2.7 between the different 
Table 1 Summary of AEs reported more than once during the study 
(treatment-emergent and including unrelated) by frequency. 
 Treatment Treatment 
 Placebo 25 mg 125 mg 500 mg 
 N=6 N=6 N=6 N=6 
Adverse event No. No. No. No. 
     
Total subjects with at least one AE 1 2 3 4 
Total number of AEs 1 2 5 9 
     
Abdominal distension - - 1 1 
Diarrhea  - - - 2 
Fatigue - 1 - 1 
Loose stools - - 1 1 
Procedural site reaction - - 2 - 
Abdominal pain  - - 1 - 
Abdominal pain upper - - - 1 
Dyspepsia - - - 1 
Headache  - - - 1 
Nausea - - - 1 
Pruritus  1 - - - 
Stye - 1 - - 
AEs reported more than once by the same subject are counted only once 
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doses. A graphical presentation of exploration for dose-proportionality of the 
pharmacokinetics of palosuran on Day 7 is shown in Figure 3. The results of the power 
model indicated that the pharmacokinetics were not dose-proportional over the entire 
dose range tested. The estimate for β  [and 95 confidence limits] was 1.6 [1.2 ; 1.7] 
and 1.6 [1.4 ; 1.7] for Cmax and AUCτ, respectively, which indicated that with increasing 
dose a more than dose-proportional increase in Cmax and AUCτ occurred. Table 3 
summarizes the pharmacokinetic parameters of palosuran in urine. Urinary excretion 
of unchanged palosuran did not exceed 3% of the dose administered. The % of dose 
excreted increased with multiple dosing and with dose, whereas the renal clearance of 
palosuran did not change. 
 
Figure 1 Mean plasma concentration versus time profile of 125 
mg palosuran b.i.d. during 6.5 days in healthy subjects 
(mean  SD, n=6).  
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On Day 1 and 7 a full profile is shown; for Day 2-6 only the trough plasma concentrations are displayed. 
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The concentration of U-II was below the LOQ or just above in all samples of the 500 
mg dose group. There was no indication that palosuran affected plasma U-II levels at 
this dose level and, therefore, the samples of lower dose groups were not analyzed. 
Due to the limited data available, no pharmacodynamic analysis could be performed. 
Total 12-hour urine volume and creatinine excreted were similar on Days 1 and 7 
(data not shown). There was a trend for an increased excretion of sodium on day 7 
when compared to day 1 whereas potassium excretion was unchanged as shown in 
Figure 4. This, however, also occurred in the placebo group. No effect of palosuran on 
any of the urinary excretion parameters could be discerned. 
 
Figure 2 Mean plasma concentration versus time profiles of 
palosuran in healthy subjects after 6.5 days of treatment 
(mean  SD, n=6 per group) on a semi-logarithmic scale. 
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Treatments were 25 mg b.i.d. (▼), 125 mg b.i.d. (), and 500 mg b.i.d. (). 
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Discussion 
While the UT system is one of the oldest conserved mechanisms involved in 
cardiovascular homeostasis over different species, its precise role in humans remains 
unclear. In recent years, agonists and antagonists of the UT receptor have been 
developed to attempt to clarify its usefulness in diseases such as diabetes, chronic 
heart failure, and renal failure [28-32].  
Palosuran is a selective, non-peptidic, orally active, potent, and competitive antagonist 
of the UT receptor, and is the first UT receptor antagonist studied in human subjects. 
In this study we confirmed the favorable tolerability profile of palosuran up to and 
Including a dose of 500 mg b.i.d. for 6.5 days. 
 
Figure 3 Dose-normalized values for AUCτ and Cmax (arithmetic mean) 
of palosuran on Day 7 and results from linear regression (with 
95% CI). 
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No SAEs were reported in this study. AEs were of mild to moderate intensity and 
resolved without sequelae. Further, no treatment-related effects on clinical laboratory 
and ECG parameters could be discerned. 
Though U-II is believed to play a role in hypertension [15], no effect on vital signs was 
observed in this healthy population. Possible explanations for the absence of any 
effect on vital signs could be a) the difference between species in function of U-II and 
the UT receptor [33,34], b) the highly variable response to U-II in humans [12,35-37], 
or c) the suggestion that the effect of U-II is associated with settings in which 
endothelial cell function is compromised and that, therefore, antagonism of the UT 
receptor would not elicit any changes in a healthy subject population [38].  
 
 
Figure 4 12-hour urinary excretion results (arithmetic mean and SD) of 
sodium (left) and potassium (right) (n = 6 for each palosuran 
dose; n = 6 for placebo). 
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Table 2  Plasma pharmacokinetic parameters of palosuran in healthy subjects after administration of 
multiple doses of 25, 125, or 500 mg b.i.d. for 6.5 days (n=6 per dose level). 
Treatment Day Cmax    (ng/ml) tmax (h) AUCτ (ng.h/ml) t1/2 (h) Accumulation Index 
25 mg bid 1 11.5 2 34.2     
(5.9, 22.3) (0.67 - 4.0) (11.1, 105)  
  7 21.5 3 84.1   21.1   2.5 
(13.1, 35.4) (0.67 - 4.0) (51.9, 136) (9.1, 49.3) (1.2, 5.0) 
125 mg bid 1 196  3 735        
(132, 290) (1.0 - 4.0) (547, 987)  
  7 431   1.3 1429    29.9  1.9 
(209, 890) (0.67 - 4.0) (1014, 2015) (21.2, 42.1) (1.4, 2.8) 
500 mg bid 1 1069        1 3350        
(676, 1689) (0.67 - 3.0) (2266, 4953)  
  7 1615       1.5 9216  23.2   2.7 
(1359, 1919) (0.67 - 6.0) (6540, 12987) (20.0, 26.9) (2.0, 3.7) 
Data are geometric means (and 95% CI) or for tmax the median (and range). 
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Palosuran was rapidly absorbed with double peaks at 1 and 4 h after administration. 
The underlying mechanism of the double-peak phenomenon is unknown and may be 
the outcome of a plethora of factors such as solubility limiting absorption due to 
physicochemical or formulation factors, complexation, enterohepatic recycling, site-
specific absorption, gastric emptying, and intestinal transit time [39]. As palosuran has a 
good solubility in water [23] it is not expected that solubility limiting absorption 
contributes significantly to the double-peak phenomenon. Palosuran was not fully 
administered in the fasted state, i.e., the evening dose was given several hours after a 
light meal, unlike the morning drug administration that was performed after an overnight 
fast. However, the double peak was also observed after the morning dose, and 
Table 3 Urine pharmacokinetic parameters of palosuran in healthy 
subjects after administration of multiple doses of 25, 125, or 
500 mg b.i.d. for 6.5 days (n=6 per dose level). 
Treatment % dose excreted in urine during 12 hours CLR (ml/min) 
25 mg bid 
Day 1 
Day 7 
 
0.45 (0.24, 0.83) 
0.56 (0.27, 1.2) 
 
54.6 (12.9, 231) 
27.6 (16.6, 46.0) 
125 mg bid 
Day 1 
Day 7 
 
0.85 (0.50, 1.4) 
2.3 (1.6, 3.5) 
 
24.2 (14.6, 39.9) 
34.0 (29.2, 39.7) 
500 mg bid 
Day 1 
Day 7 
 
0.98 (0.69, 1.4) 
2.6 (1.2, 5.5) 
 
24.3 (15.8, 37.5) 
23.4 (12.6, 43.1) 
Data are geometric means (and 95% CI) 
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therefore it is unlikely that absorption of palosuran is affected by differences in gastric 
motility, or bile salt micellular complexation in the small intestine due to food. More 
clinical data are needed to further characterize the mechanism behind the double 
absorption peaks of palosuran. 
Palosuran was eliminated in a biphasic way, with an apparent elimination half-life of 
approximately 25 h. As after 12 h palosuran plasma concentrations were low, a twice 
daily dosing regimen was considered appropriate for future studies. Using the b.i.d. 
dosing regimen, an accumulation index of approximately 2.5 was observed on Day 7. 
Steady-state conditions were attained after 4 days. Interestingly, at doses of 25 and 125 
mg b.i.d., evening trough concentrations were consistently higher than morning trough 
concentrations, though not clinically relevant due to the good tolerability profile of 
palosuran (data not shown). This phenomenon could be an example of 
chronopharmacokinetics, i.e., a difference in the disposition of palosuran during the 
night and the day [40-42]. An alternative explanation could be the intake of food. It is 
hypothesized that food reduces the bioavailability of palosuran. Indeed, in this study it 
was observed that evening trough concentrations on Day 7 were notably higher than on 
Day 6. The only striking difference between these days was a difference in the total 
daily amount of food given to the subjects, as subjects did not receive breakfast on Day 
7. Further efforts should be made to investigate the effects of food on the 
pharmaockinetics of palosuran in a dedicated study.  
Although the pharmacokinetics of palosuran were more than dose-proportional over the 
dose range tested, the wide dosing range tested in this study, the excellent tolerability of 
palosuran, and the limited increase (i.e., 2 to 3 fold), provide sufficient margins for 
further investigation of palosuran in clinical trials. Only a small amount of palosuran was 
Part II: Clinical Pharmacology of palosuran  
            in healthy subjects  
Chapter 4.  Multiple-dose PK, PD, and safety of palosuran 
 
90 
excreted unchanged in urine and renal excretion was limited. Thus, further studies with 
radio-labeled palosuran are recommended to further clarify the metabolism of the drug. 
After single-dose administration no pharmacodynamic markers could be identified that 
could guide dose selection for further studies [25] which was, in part, attributed to the 
short duration of treatment. However, in this study, after multiple-dose treatment with 
palosuran, we did not detect an effect on plasma U-II levels and urinary excretion 
parameters. Several reports in animals suggest that U-II plays an important role in the 
occurrence of renal fibrosis and dysfunction [43,44] which is substantiated by the fact 
that U-II is produced in the kidney [45]. As the (patho)physiological pathway of U-II has 
not been elucidated in patients or healthy subjects, differences in physiology could 
explain the absence of effect in healthy subjects in this study. 
In conclusion, the results of the study indicate that the U-II receptor antagonist 
palosuran is a well-tolerated drug with a pharmacokinetic profile that supports twice 
daily dosing. No pharmacodynamic markers could be identified in healthy human 
subjects, which might be attributed to a difference in function of U-II and its receptor 
between healthy subjects and patients. Thus, in order to further elucidate the 
physiological or pathophysiological mechanisms of U-II in disease, more investigations 
are needed in patients. 
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Introduction 
During drug development it is important to understand the impact of food on the 
pharmacokinetic properties of a drug that will be orally administered. Food can change 
the bioavailability of a drug by impacting different mechanisms including gastric 
emptying, bile flow, gastrointestinal pH, alteration of the luminal metabolism of the drug 
[1]. Further, food can physically or chemically interact with a substance as well as have 
an impact on enzymes involved in metabolism [2]. As the majority of drugs will be taken 
chronically, a clear dosing recommendation with regard to food intake is imperative. As 
meals with a high total calorie and fat content have a larger effect on the bioavailability 
of a drug, the effect of such a meal on the pharmacokinetics of palosuran was 
investigated in a clinical study. 
Methods 
Study subjects 
Eight healthy male subjects were recruited into this study, after providing informed 
consent. The study was approved by the Ethics Committee of Hamburg, Germany. 
Subjects had to be between 20-50 years of age, healthy as confirmed by a medical 
examination and non-smokers. The body mass index (BMI) had to be between 18 and 
28 kg/m2 and values for vital signs, ECG parameters, and clinical laboratory had to be 
either within the normal range or not deviating from normal to a clinically relevant extent. 
Study design 
The study was conducted as a single-center, open-label, randomized, 2-period 
crossover study. After screening all subjects received the following treatments: A) 
palosuran as a single dose of 125 mg in the fasted state; B) palosuran as a single dose 
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of 125 mg after the intake of a high fat, high calorie breakfast. The breakfast contained 
approximately 1000 calories, i.e., approximately 150, 250, and 600 calories from 
protein, carbohydrate, and fat, respectively, and followed the recommendations given by 
the FDA [1]. Treatments were separated by a washout of 1 week. The dose of 125 mg 
was used as this was the highest dose selected for clinical development. Safety and 
tolerability parameters were assessed at regular time points throughout the study. 
Subjects were in the clinic from 12 h before until 24 h after drug intake, during which 
time blood samples were collected for pharmacokinetic assessments. Subjects had to 
return to the clinic 36 h after drug intake for a last blood sample collection. An end-of-
study (EOS) examination was performed 2 days after study drug intake. 
Safety and tolerability assessments 
All adverse events (AE) that occurred after drug administration and up to the end-of-
study examination were recorded together with the seriousness, severity, time of onset, 
duration, and relationship to the treatment. A physical examination was performed at 
screening and at the EOS. Vital signs (supine and standing diastolic and systolic blood 
pressure and pulse rate)  and ECG (heart rate, QRS, PQ/PR, and QT and QTc 
intervals) parameters were measured at screening; immediately prior to and 1, 4, 12, 
and 24 h after drug intake; and at EOS. Clinical laboratory test parameters were 
assessed at screening and EOS. 
Pharmacokinetic sampling 
Blood samples for palosuran determination were taken immediately prior to and 0.08, 
0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, and 36 h  after study 
drug intake in tubes containing EDTA as anticoagulant. Following centrifugation at 1500 
g for 10 min at 4 ºC, plasma was separated and stored at  -20 ºC until assayed. 
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Bioanalytical method 
For the determination of palosuran in plasma, a validated liquid chromatography 
coupled to tandem mass spectrometry assay was used as described by Sidharta et. al. 
[3]. The limit of quantification (LOQ) was 1.0 ng/ml with between-run and intra-day 
coefficient of variation below 7% and 3%, respectively. 
Data analysis 
Safety and tolerability parameters were analyzed descriptively. Calculation of model-
independent pharmacokinetic parameters of palosuran was performed using 
Professional WinNonlin Version 4.0.1. (Pharsight Corp., Mountain View, California, 
USA). The maximum observed plasma concentration (Cmax) and the time to the 
occurrence of Cmax (tmax) were obtained directly from the plasma concentration-time 
curves. The area under the plasma concentration-time curve from zero to infinity (AUC0-
∞) and the half-life (t1/2) were derived by non-compartmental analysis of the plasma 
concentration-time profiles. Cmax and AUC0-∞  were assumed to be non- normally 
distributed [4]. 
Statistical analysis 
To explore differences between treatment A (fasted) and B (fed) in the 
pharmacokinetics of palosuran, log-transformed AUC0-∞ and Cmax values, and 
untransformed t1/2 values were compared with ANOVA using treatment, period, 
sequence, and subject (sequence) as factors.  
Part II: Clinical Pharmacology of palosuran  
            in healthy subjects  
Chapter 5.  Effect of food on the PK of palosuran 
 
99 
Results 
Palosuran was well tolerated in this study; no serious AEs or AEs leading to study 
discontinuation were reported. Of the 8 subjects treated, 3 subjects reported 5 AEs. Mild 
to moderate headache was the only reported AE; 2 occurred during treatment A and 3 
during treatment B. All reported cases of headache resolved spontaneously, without 
need for concomitant treatment, and resolved without sequelae. Few subjects had 
isolated changes outside of the normal range for clinical laboratory parameters that 
were not related to AEs or that showed a treatment-related pattern. Small decreases 
between EOS and baseline were observed in hemoglobin, hematocrit, and erythrocytes 
(Table 1). Four subjects presented with a blood pressure value (SBP or DBP) outside of 
the upper limit of normal at several time points, but no treatment-related pattern could 
be identified. No clinically relevant changes in ECG parameters were observed in this 
study. In all subjects ECG abnormalities were reported that were either present at 
baseline, or observed incidentally. These abnormalities were not related to AEs and no 
pattern was detected that suggested a drug effect.  
The mean plasma concentration-time curves of palosuran in the fasted and fed state 
are shown in Figure 1. The plasma concentration-time profiles of palosuran were 
characterized by two peaks at approximately 1 and 5 h without breakfast and at 2 and 5 
h with breakfast (Figure 1). The first peak tended to be less pronounced after breakfast. 
In the fasted condition and after breakfast, maximum plasma concentrations were 
reached after 1.8 h and 5 h, respectively. Maximum plasma concentrations and overall 
exposure to palosuran were slightly lower (28 and 26% reduction, respectively) after 
breakfast, but no statistically significant effect was detected. The terminal elimination 
half-life was similar without or with breakfast (16.7 h and 19.2 h, respectively). The 
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pharmacokinetic parameters of palosuran in the fasted and fed condition are 
summarized in Table 2. 
The result of the test for carry over effect was borderline statistically significant (p=0.05) 
when comparing log transformed AUC0-∞ values of treatment A and B, which was 
probably caused by the data of one subject that were different from the other 7 subjects. 
Exploratory ad hoc analysis of the data excluding subject 7 indicated a small statistically 
significant effect of treatment without carry over effect (p=0.11). In this analysis, 
exposure to palosuran expressed as AUC0-∞  was reduced by 31% (p=0.04) after 
breakfast.  
 
Discussion 
The objectives of this study were to assess the effect of food on the safety, tolerability, 
and pharmacokinetics of a single 125 mg dose of palosuran. The results of this study 
indicate that palosuran was well tolerated. No treatment-related patterns could be 
detected for any safety or tolerability variable. The most notable observations were the 
Table 1 Summary of hemoglobin, hematocrit, and erythrocytes values 
during the study. 
Laboratory 
parameter 
N 
 Absolute value Change from baseline 
Visit Median SD Median SD 
Hemolobin 
(g/dl) 
8 
Scr 15.6 1.3   
EOT 15.1 1.3 -1.0 0.3 
Hematocrit 8 
Scr 0.45 0.03   
EOT 0.43 0.03 -0.02 0.01 
Erythrocytes 
(1012/L) 
8 
Scr 4.97 0.47   
EOT 4.76 0.43 -0.25 0.11 
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decreases in hemoglobin, hematocrit, and erythrocytes that were most likely caused by 
the intense blood sampling performed in this study. 
 
 
Figure 1 Mean plasma concentration (±SD) versus time profiles of 
palosuran in healthy subjects (n = 8) in the fasted and fed state 
on linear scale. 
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Table 2 Plasma pharmacokinetic parameters of palosuran in healthy 
subjects in the fasted and fed state. 
Treatment N Cmax (ng/ml) tmax (h) AUC0- (ng.h/ml) t1/2 (h) 
A 8 92.3 
(59.7, 143) 
1.8 
(0.75-5.0) 
392 
(244, 629) 
16.7 
(12.1, 22.9) 
B 8 66.9 
(43.6, 103) 
5.0 
(2.0-6.0) 
289 
(213, 393) 
19.2 
(15.9, 23.3) 
 
Data are geometric means (95% CI); for tmax data are median (range). 
A = fasted; B = fed. 
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The only AE reported in this study was mild to moderate headache, which resolved 
spontaneously without need for concomitant medication. The good safety and 
tolerability profile of palosuran is consistent with other results reported for palosuran 
[3,5].  
The pharmacokinetic properties of palosuran in the fasted condition were also similar to 
those observed in other studies [3,5]. When given with food, a small decrease of 31% in 
AUC0-∞ was observed, mainly due to a less pronounced first peak in palosuran 
concentration. However, given the variability in palosuran concentrations, this difference 
was not considered to be clinically relevant.  
Overall, the results of this study indicate that food does not affect the safety, tolerability, 
and pharmacokinetics of palosuran. Therefore, further clinical studies of palosuran can 
be performed without specific instructions regarding food intake. 
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Abstract 
Objective: In patients with renal disease, increased urotensin-II plasma levels have 
been observed. We have investigated whether palosuran, a potent, selective, and 
competitive antagonist of the urotensin-II receptor has effects in patients who are prone 
to develop renal disease. 
Methods: Macroalbuminuric, diabetic patients, categorized by renal function, were 
treated with oral doses of 125 mg palosuran b.i.d. for 13.5 days on top of treatment with 
either an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker. 
The 24-hour urinary albumin excretion rate was determined twice at baseline and after 
13.5 days of treatment. Plasma concentrations of palosuran were determined for 12 
hours after first and last drug intake. Renal hemodynamics were measured before and 
after 12.5 days of treatment. Tolerability and safety parameters were monitored. 
Results: An overall clinically significant reduction of 24.3% (geometric mean, 95% CI: 
4.1 - 45.0) in 24-hour urinary albumin excretion rate was observed (P = 0.014). No 
effect was observed on renal hemodynamic parameters. Palosuran was rapidly 
absorbed with maximum plasma concentrations at 1 hour after drug administration. The 
accumulation factor was 1.7 (geometric mean, 95% CI: 1.3 - 2.1). Palosuran was well 
tolerated.  
Conclusions: The good tolerability profile and decrease of 24-hour urinary albumin 
excretion rate may benefit diabetic patients with renal failure with regard to their disease 
progression. Larger placebo-controlled trials in this patient population are needed to 
investigate whether urotensin-II receptor antagonists, given as mono- or combination 
therapy, may improve the current treatment of diabetic nephropathy. 
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Introduction 
Chronic renal failure is the consequence of a progressive loss of different functions of 
the kidney. If not treated, chronic renal failure may progress to end-stage renal disease, 
a serious condition that can only be treated with dialysis or renal transplantation. 
Diabetes has become the leading cause of end-stage renal disease in many parts of the 
world [1,2], partly due to the fact that prevalence of type 2 diabetes is increasing and 
that these patients live longer [3]. The earliest clinical evidence of nephropathy is the 
appearance of low but abnormal albumin levels in urine (≥ 30 mg/day), referred to as 
microalbuminuria [4-6]. Without specific intervention, 20 to 40% of the patients with type 
2 diabetic nephropathy with microalbuminuria progress to overt diabetic nephropathy, a 
condition associated with macroalbuminuria (≥ 300 mg/day). Within 20 years of onset of 
overt nephropathy, 20% of these patients will have progressed to end-stage renal 
disease [7]. To date, treatments to delay disease progression are mainly aimed at 
controlling systemic blood pressure and albuminuria [8-10]. Angiotensin-converting 
enzyme inhibitors and angiotensin receptor blockers, two drug classes inhibiting the 
renin-angiotensin-aldosterone system, not only decrease blood pressure but also 
reduce albuminuria. In addition, they have been shown to significantly decrease 
morbidity and mortality by reducing combined clinical endpoints (such as doubling of 
serum creatinine, end-stage renal disease or death) and cardiovascular events [11-16]. 
Although these findings are very promising for the treatment of patients with diabetic 
nephropathy, there is still a significant unmet medical need for new drugs that 
demonstrate an additional benefit on morbidity and mortality on top of background 
treatment with an inhibitor of the renin-angiotensin-aldosterone system. 
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Urotensin-II is a cyclic peptide described as one of the most potent vasoconstrictors 
known, though the magnitude of its effect is highly dependent on the species and 
anatomical source of the vessel [17-20]. Increased plasma urotensin-II concentrations 
have been observed in patients with diabetes, chronic heart failure, and kidney diseases 
[17,21-24]. Therefore, urotensin-II receptor antagonists may have therapeutic 
applications in these diseases [25-27]. Palosuran (ACT-058362; 1-[2-(4-benzyl-4-
hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt) is a non-
peptidic, orally active, potent, selective, and competitive antagonist of the human 
urotensin-II receptor [28]. In rat models of renal ischemia, palosuran was effective in 
both preventing post-ischemic renal vasoconstriction and in reducing post-ischemic 
acute renal failure. As the effects on renal blood flow were not accompanied by any 
systemic vasodilation, it is suggested that palosuran may have a selective renal 
vasodilating effect. Subsequently, palosuran prevented the development of acute renal 
failure and the histological consequences of ischemia [28]. In a rat model of diabetes, 
palosuran increased renal blood flow and delayed the development of proteinuria and 
renal damage [29].  
In the phase I program, palosuran was well tolerated by healthy male subjects. Its 
plasma concentration-time profile (both after single- and multiple-dosing) could be 
characterized by two peaks at approximately 1 and 4 hours after drug administration. 
The apparent elimination half-life was approximately 25 hours. Steady-state conditions 
were reached after 4 to 5 days of dosing and an accumulation of approximately 2.5 was 
observed. Less than 3% of the administered dose was excreted as unchanged drug in 
the urine. In vitro studies showed high plasma albumin binding of palosuran and no 
inhibition of cytochrome P450 enzymes or induction of CYP3A4 [30,31]. Further, it was 
suggested from in vivo studies in rats that biliary excretion is the major elimination route 
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of palosuran. In the absence of a pharmacodynamic marker, in healthy subjects, the 
effective daily dose in patients was estimated to be at 50 mg at the maximum. This was 
based on in vivo exposure in animal models and the large difference in affinity to human 
versus rat receptors [28]. In the context of this proof-of-concept study exploring only one 
dosing regimen, a dose of 125 mg b.i.d. palosuran was selected, which in healthy 
subjects had shown a high but well-tolerated exposure [30,31]. The pharmacokinetic 
profile in healthy subjects showed a pronounced distribution with a rapid and slower 
phase of disposition resulting in relatively low plasma concentrations of palosuran 
twelve hours post dose [30]. Based on these observations, a twice-daily dose regimen 
was chosen for this study.  
This report describes the first clinical study in patients with a urotensin-II receptor 
antagonist. We investigated the effects of multiple-dose palosuran on 24-hour urinary 
albumin excretion rate, renal hemodynamics, and renal function in patients with different 
degrees of renal function as well as the effect of renal impairment on the single- and 
multiple-dose pharmacokinetics of palosuran, and tolerability and safety in this 
population.  
Methods 
Study population 
Study participants were hypertensive patients of both sexes with type 2 diabetic 
nephropathy, between 30 and 75 years old, who were on stable treatment with either an 
angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker at least 
three months prior to start of the study. Arterial hypertension was defined as supine 
systolic and diastolic blood pressure above 135 mmHg and/or 85 mmHg (limits 
included), respectively. Type 2 diabetic nephropathy was defined as a medical history of 
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type 2 diabetes mellitus with an average 24-hour urinary albumin excretion rate 
between 300 mg and 3000 mg (limits included), measured twice during a two-week 
screening period with a coefficient of variation smaller than 30%. Patients were 
categorized in two groups; one with normal to mildly impaired renal function and one 
with moderately to severely impaired renal function. Renal function was defined as a 
(body surface area) corrected creatinine clearance of > 50 ml/min/1.73m2 for normal to 
mildly impaired and a (body surface area) corrected creatinine clearance of ≤ 50 
ml/min/1.73m2 for moderately impaired patients during the two-week screening period. 
Patients were excluded if they had severe concomitant diseases (e.g., unstable angina, 
severe heart failure, ventricular arrhythmias), or, specifically, clinical evidence of renal 
artery stenosis or nephrotic syndrome. Signed and dated written informed consent was 
obtained from all patients. 
Study design 
The protocol for this study was approved by the Ethics Committee of each of the three 
participating centers (Ethics Committee of Brandenburg, Cottbus, Germany; Ethics 
Committee of Baden-Württemberg, Stuttgart, Germany; and Ethics Committee of 
Schleswig-Holstein, Bad Segeberg, Germany). This study was designed as a three-
center, open-label, multiple-dose study in two groups of patients with different disease 
severity. After a screening period of about two weeks, during which the 24-hour urinary 
albumin excretion rate and the creatinine clearance were determined twice, 9 patients 
were included in the group with normal to mild renal impairment and 10 patients in the 
group with moderate to severe renal impairment. Patients were treated with 125 mg of 
palosuran twice daily for a period of 13.5 days, a dose regimen chosen based on the 
pharmacokinetic profile in healthy subjects [30,31]. For pharmacokinetic assessments, 
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blood sampling and urine collection was performed on Day 1 and Day 14 for a time 
period of 12 hours. In addition, on Day 14, urine was collected for subsequent 12 hours 
for determination of the 24-hour urinary albumin excretion rate. For renal hemodynamic 
assessments, on the day before the first study drug intake (Day -1) and after 12.5 days 
of treatment, glomerular filtration rate (GFR) and renal blood flow (RBF) were 
determined using inulin and p-aminohippuric acid clearance techniques, respectively 
[32,33]. The renal filtration fraction (FF), which represents the fraction of renal plasma 
flow filtered by the glomerulus, was calculated subsequently. Safety and tolerability 
parameters were assessed regularly throughout the study.  
Palosuran pharmacokinetics and 24-hour urinary albumin excretion 
rate 
Venous blood samples (4 ml) were collected immediately prior to study drug intake and 
0.33, 0.67, 1, 1.5, 2, 3, 4, 6, 8, and 12 h after drug intake on Day 1 and Day 14. Blood 
was collected into tubes containing EDTA and immediately centrifuged at 1500 g for 10 
minutes at 4 ºC. Plasma was separated and frozen at -20 ºC until assayed. On Day 1 
and 14, urine was collected for 12 hours after morning study drug administration. From 
the collected 12-h urine, two aliquots of 5 ml were taken and stored at -20 ºC until 
assayed. Plasma and urine concentrations of palosuran were determined using a 
validated liquid chromatography assay coupled to tandem mass spectrometry operating 
in the positive ionization detection mode. The limit of quantification was 1.0 ng/ml 
(between-run coefficients of variation below 7.4% and 4.2% for plasma and urine, 
respectively). On Day 14, urine was collected for subsequent 12 hours. From the pooled 
24-hour urine, two aliquots of 5 ml were taken and 24-hour urinary albumin excretion 
rate was determined. 
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Renal hemodynamics 
For determination of GFR and RBF a loading dose of inulin (Inutest®; Fresenius Kabi, 
Linz, Austria) and p-aminohippuric acid (Clinalfa®; Merck Biosciences AG, Läufelingen, 
Switzerland) was administered on the basis of the body weight of the patient, followed 
by a maintenance infusion to keep inulin and p-aminohippuric acid at steady state. The 
infusion regimen was based on the creatinine clearance determined during the 
screening phase. Three venous blood samples of 1.2 ml each were taken at 1, 1.5 and 
2 hours after infusion start (i.e., when inulin and p-aminohippuric acid were in steady 
state). The infusion was started 2 hours after the (theoretical) morning drug intake to 
assure that the measurement was performed around the tmax  of palosuran. Blood was 
collected into tubes containing EDTA and immediately centrifuged at 1500 g for 10 
minutes at 4 ºC. Plasma was separated and frozen at -20 ºC until assayed. From the 
infusion solution a sample of 2 ml was taken and frozen at -20 ºC for inulin and PAH 
determination. Inulin concentrations of the plasma and infusion samples were 
determined using an enzymatic assay based on the method of Kuehnle et al. [34]. The 
limit of quantification was 5 μg/ml (between-run coefficients of variation below 9.2%). p-
Aminohippuric acid concentrations were determined using a high performance liquid 
chromatography assay with ultraviolet detection that was adapted from the method of 
Marsilio et al. [35]. The limit of quantification was 1.2 μg/ml (between-run coefficients of 
variation below 16.0%). 
Tolerability and safety assessments 
Tolerability and safety were evaluated using spontaneously reported adverse events, 
physical examination, measurements of vital signs (supine diastolic and systolic blood 
Part III: Clinical Pharmacology of palosuran  
             in Type 2 DM patients  
Chapter 6.  PD and PK of palosuran  
 
113 
pressure, and pulse rate), ECG and laboratory test parameters (including fructosamine, 
Hb A1C, insulin, and hematocrit), performed before, during and after the study.  
Data analysis 
GFR is identical to inulin clearance, which was determined by the ratio of the infusion 
rate of inulin (accurately assessed) and its steady-state plasma concentration. The latter 
was given by the mean of 3 separate measurements. The RBF was calculated as RBF 
= RPF / (1- hematocrit), where RPF represents the renal plasma flow. The hematocrit 
was taken from the clinical laboratory report obtained closest to the assessment day.  
RPF was calculated by the ratio of the infusion rate of PAH (accurately assessed) and 
its steady-state plasma concentration. The latter was given by the mean of 3 separate 
measurements. The filtration fraction (FF) was calculated as FF = GFR / RPF.  
Calculation of model-independent pharmacokinetic parameters for palosuran was 
performed using Professional WinNonlin Version 4.0.1. [36]. The maximum plasma 
concentration (Cmax) and the time of its occurrence (tmax) were obtained from individual 
data. The area under the plasma concentration versus time curve during one dosing 
interval of 12 h (AUCτ) was calculated using the linear trapezoidal rule. The 
accumulation index was defined as AUCτ Day 14/ AUCτ Day 1 [37].  
From the urine concentrations of palosuran, the renal clearance (CLR) and % of total 
dose excreted as unchanged drug were calculated.  
Statistical analysis 
To explore differences between the mean of the screening values and the 24-hour 
urinary albumin excretion rate after 13.5 days of treatment, logarithmically transformed 
24-hour urinary albumin excretion rate values were compared using the Wilcoxon 
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Paired Signed Rank test (2-sided, α=5%). It was chosen to logarithmically transform the 
24-hour urinary albumin excretion rate, as these values are not normally distributed due 
to the nature of the patient population. 
To explore differences within each renal function group on the renal hemodynamic 
parameters GFR, RBF, and FF, untransformed values of Day 1 and 13 were compared 
using the Wilcoxon Paired Signed Rank test (2-sided, α=5%).  
To explore differences between the two groups, untransformed changes from baseline 
of GFR, RBF, and FF were compared using the Signed Rank Wilcoxon test (2-sided, 
α=5%).  
To confirm that the degree of renal function was different between the two groups at 
baseline, untransformed GFR, RBF, and FF values on Day -1 were compared using the 
Signed Rank Wilcoxon test (2-sided, α=5%).  
Comparisons of pharmacokinetic parameters between the two renal function groups 
were performed using a two-sample t-test (2-sided, α=5%) for log-transformed AUCτ 
and Cmax and the Signed Rank Wilcoxon test (2-sided, α=5%) for untransformed tmax 
and accumulation index. To explore differences within each renal function group log-
transformed AUCτ and Cmax and untransformed tmax values of Day 1 and 14 were 
compared using the Wilcoxon Paired Signed Rank test (2-sided, α=5%). 
Results 
One patient in the group with moderately impaired renal function withdrew consent on 
Day 6 of the study. This patient was, therefore, only analyzed for safety. The other 18 
patients completed the study according to the protocol, although another patient in the 
group with moderately impaired renal function was not included in the pharmacokinetic 
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and renal hemodynamic analyses, due to missing samples. Table 1 summarizes the 
demographic characteristics of those patients who received treatment. 
Table 2 summarizes the 24-hour urinary albumin excretion rate values categorized by 
renal function group at baseline and after 13.5 days of treatment. Individual changes 
from baseline after 13.5 days of treatment in 24-hour urinary albumin excretion rate 
categorized by renal function are presented in Figure 1. Comparison of the geometric 
means between Day 14 and baseline revealed a statistically significant decrease of 
26.2% (geometric mean, 95% CI: 5.0 – 46.3) in the group with normal to mild renal 
impairment (P = 0.027). In the group with moderate to severe renal impairment a 
decrease of 22.3% (geometric mean, 95% CI: -11.6 – 45.0) was observed, however, 
this finding was not statistically significant (P = 0.250). The overall change in geometric 
means of 24-hour urinary albumin excretion rate from baseline to Day 14 was a 
decrease of 24.3% (geometric mean, 95% CI: 4.1 – 45.0) with P = 0.014. 
Table 3 summarizes the renal hemodynamic parameters of the two renal function 
groups. Analysis of the GFR data plotted versus the corrected CrCl data by means of 
linear regression demonstrated a good correlation between these two parameters (r = 
0.90). At baseline (Day -1) GFR and RBF were statistically significantly lower in the 
group with moderate to severe renal impairment. No statistically significant difference 
was observed in FF. Results from the statistical analyses showed no statistically 
significant change from Day -1 to Day 13 in GFR and FF for both renal function groups. 
For RBF a statistically significant decrease of 7.7% was observed in the group with 
moderate renal impairment (P = 0.023), however, this change is deemed not to be 
clinically relevant. No statistically significant differences were observed when comparing 
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the changes from baseline in GFR, RBF, and FF between the two renal function groups 
(P > 0.050). 
 
The mean plasma concentration-time profiles of palosuran for the two renal function 
groups are shown in Figure 2. The plasma concentration-time profiles after a single oral 
dose of palosuran and after 13.5 days of treatment were similar in both groups and 
could be characterized by rapid absorption with a peak at approximately 1 hour. Some 
patients showed a second peak at 2 hours, but this double-peak phenomenon was less 
frequently observed on Day 14. No statistically significant differences between the two 
groups were detected for any plasma pharmacokinetic parameter (P > 0.050), nor was 
any statistically significant change detected from Day 1 to Day 14 within each renal 
function group (P > 0.050). 
Table 1 Demographic data summary. 
 
Corrected creatinine clearance 
 > 50 ml/min/1.73m2 (n=9) 
Corrected creatinine clearance  
<= 50 ml/min/1.73m2 (n=10) 
Sex [n (%)]   
Males          8 (88.9)          9 (90.0) 
Females          1 (11.1)          1 (10.0) 
Age (y) [mean (SD)]   65.2 (8.5)     62.7 (10.2) 
Weight (kg) [mean (SD)]     94.1 (27.8)     88.9 (14.4) 
Height (cm) [mean (SD)] 175.4 (8.0) 173.7 (7.9) 
BMI (kg/m2) [mean (SD)]   30.3 (7.7)   29.4 (4.0) 
Caucasian/white race  100% 100% 
Antihypertensive treatment  [n (%)] 
ARB           1 (11.1)          3 (30.0) 
ACEI           8 (88.9)          7 (70.0) 
Antidiabetic treatment  [n (%)]   
No therapy           3 (30.0) 
Monotherapy   
Insulin           4 (44.4)          4 (40.0) 
Sulphonylureas           2 (22.2)          1 (10.0) 
Meglitinides           1 (10.0) 
Combination therapy   
Insulin + metformin           1 (11.1)  
Insulin + α-glucosidase inhibitor           1 (10.0) 
Metformin + meglitinide           1 (11.1)  
Metformin + sulphonylureas           1 (11.1)  
Hemoglobin A1C        6.98 (0.79)     7.10 (0.89) 
Serum creatinine (mol/l) [mean (SD)]    103 (26)   245 (77) 
Corrected creatinine clearance  
(ml/min/1.73m2) [mean (SD)]      89.7 (35.7)   30.4 (7.9) 
  
BMI = body mass index; ARB = angiotensin receptor blocker; ACEI = angtiotensin-converting enzyme inhibitor. 
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Figure 1 Individual 24-hour urinary albumin excretion rate values at 
baseline and after 14 days of treatment with 125 mg palosuran 
b.i.d.  
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P = 0.027 when comparing Day 14 to baseline for the group with corrected creatinine clearance > 50 ml/min/1.73 m
2
. P = 
0.250 when comparing Day 14 to baseline for the group with corrected creatinine clearance  50 ml/min/1.73 m
2
. 
Table 2 24-hour urinary albumin excretion rate values by renal function 
group and for the groups combined.  
 N 
24-hour urinary albumin 
excretion rate 
(mg/24h) 
P value* 
Corrected creatinine clearance 
 > 50 ml/min/1.73m2  
   
Baseline 9   944 (506 - 2416)  
Day 14 9   696 (317 - 2141) 0.027 
Corrected creatinine clearance  
< 50 ml/min/1.73m2 
   
Baseline 9 1255 (518 - 2961)  
Day 14 9   975 (285 - 2430) 0.250 
All patients     
Baseline 18 1088 (576 - 2416)  
Day 14 18   824 (374 - 1727) 0.014 
  
BMI = body mass index; ARB = angiotensin receptor blocker; ACEI = angtiotensin-converting enzyme inhibitor. 
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A summary of the plasma pharmacokinetic parameters is shown in Table 4. The 
accumulation index for the group with normal or mild renal impairment was 1.5 
(geometric mean, 95% CI: 1.2 - 2.0) and for the group with moderate to severe renal 
impairment 1.8 (geometric mean, 95% CI: 1.2 - 2.7) (P > 0.050). 
A summary of the urine pharmacokinetic parameters is shown in Table 5. In the group 
with normal to mildly impaired and that with moderately to severely impaired renal 
function, on average less than 1% and 0.7% of the administered dose, respectively, was 
excreted unchanged in urine. The renal clearance of palosuran was higher in the group 
with normal to mildly compared to that with moderately to severely impaired renal 
function (48.4 ml/min vs. 28.6 ml/min and 50.3 ml/min vs. 32.2 ml/min on Day 1 and Day 
14, respectively).  
No serious adverse events or adverse events that led to premature withdrawal from the 
study were reported. Of the 19 patients treated with palosuran, 17 reported a total of 43 
adverse events. The most frequently reported adverse event was “feeling hot”, which, 
Table 3 Renal hemodynamic parameters in patients grouped by renal 
function.  
 N GFR (ml/min) RBF (ml/min) FF 
Corrected creatinine clearance 
 > 50 ml/min/1.73m2  
    
Day -1 9 82.6 (63.3 - 108) 767 (566 - 1040) 0.19 (0.16 - 0.22) 
Day 13 9 91.8 (67.5 - 125) 698 (477 - 1022) 0.21 (0.18 - 0.25) 
Corrected creatinine clearance  
<= 50 ml/min/1.73m2  
    
Day -1 8 30.7* (20.3 - 46.6) 271* (191 - 385) 0.18 (0.13 - 0.25) 
Day 13 8 42.2 (29.7 - 60.0) 250# (181 - 344) 0.26 (0.19 - 0.37) 
 
 
Data are geometric means (and 95% CI).  
GFR = Glomerular filtration rate; RBF = renal blood flow; FF = filtration fraction. 
*P < 0.050 vs. Day - 1 of the group with a corrected creatinine clearance >50 ml/min/1.73m
2
. 
 
#
P = 0.023 versus Day -1. 
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with regard to time and duration of the inulin/PAH infusion, is most likely related to the 
infusion of inulin/p-aminohippuric acid, though a relation between study drug and 
adverse event cannot be completely excluded. In addition, only headache, fatigue, 
nasopharyngitis, and vertigo were reported more than once. 
 
A summary of the most frequently reported adverse events including those adverse 
events judged to be unrelated to study treatment is provided in Table 6. Most adverse 
events were of mild to moderate intensity and all adverse events resolved without 
sequelae. No effects of palosuran on hematology and biochemistry parameters, vital 
signs (including blood pressure), physical examination, or ECG parameters could be 
detected. 
Figure 2 Arithmetic mean plasma concentration (SD) versus time 
profiles (0-12 hours) of palosuran in patients categorized by 
renal function group (linear scale).  
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No statistically significant differences were observed when comparing the group with a corrected creatinine clearance 
>50 ml/min/1.73m
2
 versus  50 ml/min/1.73m
2
 and when comparing Day 14 to Day 1 within each renal function group. 
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Discussion 
To the best of our knowledge, this study is the first in which a urotensin-II antagonist 
has been administered to patients who are prone to cardiovascular disease. While the 
peptide urotensin-II, an endogenous agonist of the urotensin-II receptor has been 
 
known for over four decades, the urotensin-II receptor itself has only recently been 
characterized and its function is still not fully understood [19]. Urotensin-II receptors  are 
predominantly present in human heart and arterial vessels, suggesting urotensin-II, 
which is shown to be a more potent vasoconstrictor than endothelin-1, to be of 
importance as a cardiovascular mediator [19-23]. Indeed, in patients with renal failure 
increased plasma urotensin-II levels (2-3 fold greater than control) have been observed, 
suggesting that a urotensin-II receptor antagonist could have a therapeutic role in such 
patients [20-26].  
Table 4 Plasma pharmacokinetic parameters of palosuran in patients 
grouped by renal function (125 mg palosuran twice daily for 
13.5 days).  
 N 
Cmax 
(ng/ml) 
tmax 
(h) 
AUC 
(ng.h/ml) 
Accumulation 
index 
Corrected creatinine 
clearance 
 > 50 ml/min/1.73m2 
    
 
Day 1 9 139 (76.5 - 254) 1.0 (0.67-4.0) 283 (171 - 470)  
Day 14 9 135 (70.6 - 259) 1.5 (0.67-4.0) 433 (281 - 668) 1.5 (1.2 - 2.0) 
Corrected creatinine 
clearance  
< 50 ml/min/1.73m2 
    
 
Day 1 8 109 (44.1 - 271) 1.3 (0.55-4.0) 235 (118 - 470)  
Day 14 8 107 (46.8 - 243) 1.5 (0.67-3.0) 429 (261 - 703) 1.8 (1.2 - 2.7) 
  
Data are geometric means (and 95% CI); for tmax data are median (range). 
No statistically significant differences were observed either within or between the 2 renal function groups. 
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Palosuran is a non-peptidic, specific antagonist of the urotensin-II receptor and has 
been studied in preclinical disease models and healthy human subjects [28-31]. In rat 
 
 
Table 6 Summary of adverse events reported more than once during 
study (treatment-emergent and unrelated to treatment) by 
frequency. 
 Number of events 
System Organ Class/ 
Preferred Term 
Corrected creatinine clearance 
> 50 ml/min/1.73m2 (n=9) 
Corrected creatinine clearance 
<= 50 ml/min/1.73m2 (n=10) 
Total (n=19) 
Feeling hot 5 5 10 
Headache  4 3 7 
Fatigue 1 1 2 
Nasopharyngitis - 2 2 
Vertigo  1 1 2 
  
Table 5 Urine pharmacokinetic parameters of palosuran in patients 
grouped by renal function (125 mg palosuran twice daily for 
13.5 days). 
 N % dose excreted unchanged in urine CLR (ml/min) 
Corrected creatinine 
clearance 
 > 50 ml/min/1.73m2 
   
Day 1 9 0.66 (0.35 - 1.3) 48.4 (35.7- 65.5) 
Day 14 9   1.0 (0.60 - 1.8) 50.3 (35.4 - 71.5) 
Corrected creatinine 
clearance  
< 50 ml/min/1.73m2 
   
Day 1 8   0.32 (0.14 - 0.72) 28.6 (20.7 - 39.5) 
Day 14 8 0.66 (0.35 - 1.2) 32.2 (22.0 - 47.0) 
 
 
Data are geometric means (and 95% CI).  
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models of acute renal failure and diabetes, palosuran significantly improved renal 
function, decreased the number of tubular and tubulointerstitial lesions, and improved 
survival [28,29]. Preclinical data also suggested that palosuran exhibited selective renal 
vasodilating effects [28], indicating that compared to angiotensin-converting enzyme 
inhibitors and angiotensin receptor blockers, which induce systemic vasodilation, 
palosuran has a completely different mode of action. In healthy male subjects, good 
tolerability and convenient pharmacokinetic properties were observed, permitting us to 
investigate palosuran in diabetic patients [30,31]. 
The most interesting observation of this study was that after 13.5 days of treatment, the 
24-hour urinary albumin excretion rate had, compared to baseline, statistically 
significantly decreased with 26.2% (geometric mean, 95% CI: 5.0 – 46.3, P = 0.027) in 
the group with normal to mildly impaired renal function. A decrease of 22.3% (geometric 
mean, 95% CI: - 11.6 - 45.0) was observed in the group with moderately to severely 
impaired renal function, although this difference did not reach statistical significance (P 
= 0.250). 
Although the relationship between 24-hour urinary albumin excretion rate and effect on 
renal function has not been completely elucidated, 24-hour urinary albumin excretion 
rate is accepted as a clinical marker for cardiorenal disease [38-40]. Therefore, a 
decrease of the magnitude found in this study would be clinically significant and 
beneficial with regard to the patient’s disease progression [38]. As this study was not 
powered to prove statistical significance on 24-hour urinary albumin excretion rate, the 
overall decrease of 24.3% (geometric mean, 95% CI: 4.1 – 45.0, P = 0.014) is a strong 
indication of a drug-related effect. The trial ended with this 24-urinary albumin excretion 
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rate assessment, hence, no data is available on the reversibility of the reduction of 
albuminuria.  
The corrected creatinine clearance is used as an estimate of the GFR, whereas the 
GFR determined by inulin infusion is the standard to assess kidney function. Statistical 
analysis of GFR and RBF at baseline confirmed that the groups studied were 
significantly different regarding these parameters. However, no clinically relevant 
changes in the renal function parameters GFR, RBF, and FF were observed between 
baseline and after 12.5 days of treatment with palosuran. Importantly, the renal 
hemodynamic assessments were performed 2 hours after morning study drug intake to 
ensure sufficient exposure to palosuran. Review of the individual plasma concentration-
time profiles showed that all patients were exposed to palosuran at the time of the renal 
hemodynamic assessments. As known from studies performed by Björck et al. [41] and 
Buter et al. [42], effects on renal hemodynamic parameters can already be seen after 
nine days of treatment with angiotensin-converting enzyme inhibitors and after three 
days of treatment with angiotensin receptor blockers. Therefore, the treatment period of 
two weeks with palosuran should have been sufficient to observe any effects, unless 
urotensin-II receptor antagonists are associated with an unusually slow onset of action. 
One of the reasons, why treatment with palosuran did not significantly influence renal 
function parameters may be the fact that all patients included in the current study were 
treated either with an angiotensin-converting enzyme inhibitor or angiotensin receptor 
blocker. As both of these drug classes are associated with changes in renal 
hemodynamics in diabetic patients [41,42], such effects associated with palosuran may 
have been masked. Due to the proven efficacy of angiotensin-converting enzyme 
inhibitors and angiotensin receptor blockers in reducing macroalbuminuria in diabetic 
patients, for ethical reasons, patients in this trial were not discontinued from their normal 
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treatment. However, it may be worthwhile to perform a trial in a small number of drug-
naive patients to investigate effects of palosuran per se on renal hemodynamics and on 
the 24-hour urinary albumin excretion rate. 
The mechanism behind the lowering of 24-hour urinary albumin excretion rate remains 
unknown, but appears to be independent of changes in renal hemodynamics as no 
significant effects of palosuran on RBF and GFR could be observed. This is in contrast 
to the study performed by Buter et al. [42] in which consistent effects on urinary albumin 
excretion rate and renal hemodynamics could be observed after 3 days of treatment 
with an angiotensin receptor blocker in patients with type 1 diabetes mellitus. The 
increased urinary excretion of albumin is a marker of glomerular damage. In addition, 
albumin acts directly or indirectly on tubular cells and elicits a tubular cell response 
which promotes tubulointerstitial inflammation. The infiltrating interstitial macrophages 
and T-lymphocytes are considered to play an important role in the progression of 
glomerulosclerosis [43]. Numerous recent studies indicate that the accumulation of 
albumin in proximal tubules promotes tubulointerstitial inflammation resulting in 
endothelial dysfunction [36,40,44,45]. Therefore, palosuran may have a direct, so far 
not specified action on the tightness of the renal endothelia in patients with type 2 
diabetes mellitus and macroalbuminuria.  
This study showed that the plasma concentration-time profiles of palosuran in patients 
with different degrees of renal function are similar. Although the exposure to palosuran 
in the group with moderate to severe renal impairment was slightly lower than in the 
group with normal to mildly impaired renal function, this difference was negligible. 
Therefore, the plasma concentration-time profile in patients can be characterized by a 
rapid absorption with a peak at 1 hour after study drug intake, accumulation of 1.7-fold 
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(geometric mean, 95% CI: 1.3 - 2.1), and limited renal excretion of unchanged drug 
(< 1%). In healthy human subjects, a second peak of palosuran at around 4 hours had 
been observed[30,31], which was not present in the patient population. As palosuran is 
probably mainly metabolized through the liver and excreted into the bile, no major 
difference in renal excretion was observed between healthy subjects and patients with 
renal impairment. Interestingly, exposure to palosuran (in terms of Cmax and AUCτ), in 
comparison with healthy subjects was lower in patients, though the reason is yet 
unknown. As the dose given to patients (i.e., 125 mg b.i.d.) was based on the 
pharmacokinetics of palosuran in healthy subjects, dose adjustment might be required 
in patients. It could be hypothesized that the exposure in patients was not sufficient to 
elicit an effect on renal hemodynamics, even though an effect on albuminuria was 
observed. Palosuran is highly bound (96%, unpublished data) to plasma albumin in 
humans. Several co-medications administered in this patient population (e.g., the 
angiotensin receptor blocker losartan and the antidiabetic drugs tolbutamide and 
repaglinide) are known to have high plasma albumin binding as well [46-48] and, 
therefore, possible drug-drug interactions due to changes in pharmacokinetic 
parameters could theoretically occur. The clinical relevance of changes in plasma 
protein binding has been discussed by Benet and Hoener [49]. As palosuran is 
administered orally, mainly excreted through the liver, and it is expected that the 
therapeutic window is large, we conclude that the occurrence of drug-drug interactions 
is unlikely and, therefore, do not expect that dosing regimens should be adapted for an 
altered unbound fraction. Larger studies with different doses or dosing regimens should 
provide more insight in the pharmacokinetics of palosuran in different patient groups.  
Palosuran was very well tolerated. No serious adverse events or adverse events that 
led to premature withdrawal from the study were reported. The most frequently reported 
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adverse events were “feeling hot” and headache, of which the first is probably related to 
the infusion of inulin and p-aminohippuric acid as this was not observed in healthy 
subjects [30,31]. No clinically relevant changes in ECG, or clinical laboratory test 
parameters were observed in this study, in line with the phase I observations. Also in 
line with preclinical results, no effects on vital signs were observed in these patients. 
Although the effect on blood pressure with monotreatment of palosuran in patients has 
not been studied yet, it appears that palosuran indeed lowers the 24-hour urinary 
albumin excretion rate through a different mechanism than the current therapies 
(angiotensin-converting enzyme inhibitors or angiotensin receptor blockers). 
In conclusion, palosuran on top of treatment with an angiotensin-converting enzyme 
inhibitor or angiotensin receptor blocker decreases albuminuria in macroalbuminuric 
patients with type 2 diabetes mellitus without influencing renal or systemic 
hemodynamics. The observed reduction in 24-hour urinary albumin excretion rate can 
most likely be explained by renal and not by systemic actions, although in this study no 
change in renal hemodynamics was observed. Since the magnitude of this effect 
appears to be clinically relevant even in patients treated with angiotensin-converting 
enzyme inhibitors or angiotensin receptor blockers, larger and  placebo-controlled 
studies with palosuran in this patient population should be initiated to investigate 
whether or not urotensin-II receptor antagonists could be utilized, as a combination or 
mono therapy, in the treatment of diabetic nephropathy. 
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What is already known about this subject? 
 Urotensin-II (U-II) is one of the most potent vasoconstrictors identified thus far. Though differences in 
both U-II blood levels and U-II receptor (UT-receptor) expression have been observed in patients with 
cardiovascular and cardiorenal disease, the precise function in humans has not been elucidated. 
 U-II and its receptor have been reported to be involved in glucose metabolism and insulin resistance, 
which can lead to the development of type 2 diabetes mellitus. 
 In rat models of diabetes, palosuran, a selective, potent antagonist of the human UT-receptor 
improved several disease markers.  
What this study adds 
 In this study in diabetic patients, the effects of palosuran on insulin secretion and sensitivity were 
investigated using a hyperglycemic glucose clamp and a meal tolerance test and daily glucose levels 
were also studied. Although no obvious beneficial effect of palosuran in this patient population was 
observed, the study contributes to providing more insight in the human U-II/UT receptor system.  
Published in: Br J Clin Pharmacol 2009;68(4):502-10. 
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Abstract 
Aim: To investigate the effects of palosuran, a non-peptidic, potent, and selective 
antagonist of the urotensin-II receptor on insulin and glucose regulation in 20 diet-
treated patients with type 2 diabetes mellitus in a double-blind, placebo-controlled, 
randomized, crossover, proof-of-concept study.  
Methods: After 4 weeks of oral treatment with 125 mg palosuran or placebo b.i.d., 
effects on insulin secretion and sensitivity and blood glucose levels were assessed by 
means of a hyperglycemic glucose-clamp, meal tolerance test, Homeostasis Model 
Assessment-Insulin Resistance (HOMA-IR) score, and daily self monitoring of blood 
glucose (SMBG). Plasma concentrations of palosuran were determined for 12 hours 
on the last day of intake. 
Results: Palosuran did not affect second-phase insulin response (primary endpoint) 
during the hyperglycemic glucose-clamp in comparison to placebo (paired difference 
of -1.8 μU/ml with 95% confidence interval of -7.8, +4.2). Likewise, no effects of 
palosuran were detected on the first-phase insulin response, as on insulin secretion 
and blood glucose levels during the meal tolerance test or on HOMA-IR score. No 
clinically significant effects on daily blood glucose profiles were observed during the 
study. Geometric mean Cmax, and AUC (95% confidence interval) and median tmax 
(range) in this patient population were 180 (125, 260) ng/ml, 581 (422, 800) ng.h/ml, 
and 3.0 (0.67, 4.3) h, respectively.  
Conclusions: The results of this study indicate that antagonism of the U-II system 
does not influence insulin secretion or sensitivity or daily blood glucose levels in diet-
treated patients with type 2 diabetes. 
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Introduction 
The prevalence of type 2 diabetes mellitus has increased dramatically in the last 
decades, being the seventh leading cause of death in the United States, and affecting 
the quality of life in a majority of the patients [1,2]. Important characteristics of type 2 
diabetes are impaired insulin action (insulin resistance) and an altered endogenous 
insulin secretion pattern caused by a defective pancreatic β-cell response to glucose 
(insulin deficiency), of which the latter is predictive of overt type 2 diabetes mellitus [3-
5]. The gold standard for estimation of β-cell secretory capacity is the hyperglycemic 
glucose-clamp [6]. Using this clamp technique, the β-cell response is evaluated by 
exposure to the insulin secretagogue glucose. When measured in healthy subjects, the 
β-cell response to glucose is biphasic in nature with an early burst of insulin release 
within the initial 10 minutes after an increase in blood glucose levels and a second 
phase characterized by a progressive increase in insulin secretion lasting several hours 
[7]. As glucose tolerance progresses to full-blown diabetes, the first-phase insulin 
response diminishes [7-9].  
Treatment of patients in early stages of type 2 diabetes is aimed at increasing β-cell 
function and lowering insulin resistance in order to lower blood glucose levels. Though 
an array of antidiabetic drugs is currently available, treatment can be associated with 
several acute and long-term side effects ranging from profound hypoglycemia to 
congestive heart failure [10-12]. Therefore, there is still an unmet need for better and 
safer antidiabetic drugs. 
Urotensin-II (U-II) is a cyclic peptide described as one of the most potent 
vasoconstrictors known, though the magnitude of its effect is highly dependent on the 
species and anatomical source of the vessel [13]. In the isolated perfused rat pancreas, 
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U-II blocked the release of insulin in response to glucose and arginine by acting directly 
on the β-cells [14]. Increased plasma U-II concentrations have been observed in 
patients with diabetes, chronic heart failure, and kidney diseases [15-17]. Further, a 
correlation between polymorphism of the gene encoding U-II and glucose intolerance 
has been identified in Japanese patients with diabetes mellitus [18,19]. Therefore, 
Urotensin-II receptor (UT receptor) antagonists may have a therapeutic potential in 
patients with diabetes, as well as in patients with diabetic nephropathy [16,17,20]. 
Palosuran is a non-peptidic, orally active, potent antagonist of the human UT receptor 
[21]. In rat models of renal ischemia, palosuran was effective in both preventing the post 
ischemic renal vasoconstriction and in reducing the post ischemic acute renal failure 
[21]. Subsequently, palosuran prevented the development of acute renal failure and the 
histological consequences of ischemia [21]. In a rat model of diabetes, palosuran 
increased renal blood flow, delayed the development of proteinuria and renal damage 
and improved survival [22]. In addition, palosuran had significant beneficial effects on 
glycemia, serum cholesterol, triglycerides, and HbA1C. In this rat model, administration 
of palosuran increased insulin concentrations moderately, but significantly [22].  
In the palosuran phase I development program, conducted in healthy male subjects, no 
remarkable safety findings were detected following administration of palosuran up to 
high doses (2000 mg as a single dose and 500 mg b.i.d.). The plasma-concentration 
profile revealed a rapid and slower phase of elimination, resulting in low plasma 
concentrations of palosuran 12 hours post dose. These findings indicated that twice-
daily dosing would be the most appropriate dosing regimen. Using this dosing regimen 
the accumulation index was approximately 2.5 [23,24]. Urinary excretion of unchanged 
drug in healthy subjects was less than 3% of the administered dose and in vitro studies 
showed no indications of cytochrome P450 inhibition [21,23,24].  
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Based on the observations of elevated U-II levels in patients with diabetes and the 
beneficial effect of palosuran in rat models of diabetes, we investigated the effects of 
multiple-dose palosuran treatment on insulin secretion and sensitivity and daily glucose 
levels, as well as the pharmacokinetics and safety and tolerability of palosuran, in 
patients with type 2 diabetes mellitus. The primary objective of this study was to 
investigate the second-phase insulin response during a hyperglycemic glucose-clamp to 
palosuran in comparison to placebo. Although the first-phase insulin response provides 
useful insights into the pathophysiology of type 2 diabetes, it may only reflect limited 
aspects of the complex process of insulin secretion, may be relatively insensitive to 
subtle change in function. In order to investigate the effects of palosuran per se, a diet-
treated patient population was selected. A dose regimen of 125 mg b.i.d. was selected 
for this proof-of-concept study, as in a previous pilot study in patients with diabetic 
nephropathy a decrease in 24-hour albumin excretion rate, an accepted clinical marker 
for cardiorenal disease, was demonstrated, and, had been well tolerated in both healthy 
subjects and patients [23-25]. 
Methods 
Study population 
Study participants were patients of either sex, between 30 and 65 years of age, with 
type 2 diabetes mellitus treated by diet only, fasting blood glucose level between 110 
and 180 mg/dl (6.1 and 10.0 mmol/l, limits included), and stable HbA1C below 8.5%. 
Patients were excluded if they were women of childbearing potential, were treated with 
an antidiabetic drug in the two months before screening, if they had severe concomitant 
diseases, or, more specifically, had evidence of diabetes complications. 
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Study design 
The protocol for the study was approved by the Ethics Committee of the Ärztekammer 
Nordrhein, Düsseldorf, Germany. The study was conducted as a mono-center, double-
blind, placebo-controlled, randomized, two-way crossover study. In random order, 
patients were treated with 125 mg palosuran or placebo twice daily for a four week 
treatment period and, after a 4-week wash-out period, switched to the alternative 
treatment. Every treatment period started with an assessment of baseline and safety 
parameters. After 15 days of treatment a check-up visit was performed, which consisted 
of safety, blood glucose, and insulin assessments. After 28 and 29 days of treatment a 
meal tolerance test and a hyperglycemic glucose-clamp were performed, respectively. 
In addition, samples for pharmacokinetic evaluations were taken during a 12-hour 
interval on the day of the hyperglycemic glucose-clamp. Patients were requested to 
practice self-monitoring of blood glucose (SMBG) during the whole course of each 
treatment period. At the end of each treatment period, safety parameters were 
assessed and, finally, patients were followed-up for 4 weeks after the last study drug 
intake. Patients were in the clinical research institute on the first day, for the check-up 
visit on day 15, and during the meal tolerance test and hyperglycemic glucose-clamp 
assessments on days 28 and 29, respectively. At each visit, capsules with the study 
drug were counted to check the compliance. In addition, patients were requested to 
record the drug intake times at home in a patient diary. 
Hyperglycemic glucose clamp 
The hyperglycemic glucose-clamp was performed under fasted conditions. Patients 
were in supine position with catheters inserted into antecubital veins for infusion of 20% 
glucose solution and drawing of blood samples. For continuous measurement of 
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arterialized venous blood glucose by means of an artificial pancreas (Biostator, mtb 
Medizintechnik, Ulm, Germany), another catheter was inserted into a dorsal hand vein. 
Arterialization of venous blood was achieved by using the heated hand technique with 
the hand placed in a box in which the air was warmed to approximately 55°C. One hour 
after study drug intake the hyperglycemic glucose-clamp procedure was started which 
consisted of administration of an intravenous loading dose of 20% glucose solution 
(Glucose 20 pfrimmer, Baxter Germany GmbH, Unterschleissheim, Germany) adjusted 
to the patient’s bodyweight (150 mg/kg), followed by a 20% glucose solution infusion 
regulated by means of the Biostator in order to increase the patient's blood glucose to 
the target level of 240 mg/dl. Subsequently to the loading dose the blood glucose was 
maintained for 120 minutes at that target level by a variable infusion of 20% glucose 
solution applied by the Biostator. For the determination of the baseline, three samples 
were taken at 10-minute intervals before the start of the clamp procedures. During the 
entire course of the hyperglycemic glucose-clamp patient’s blood glucose levels and 
glucose infusion rates (GIR) were recorded by the Biostator on a minute-to-minute 
basis. Blood samples for serum insulin measurements were drawn every 2 minutes for 
the first 10 minutes and thereafter every 10 minutes using a local laboratory method.  
Meal tolerance test 
The meal tolerance test was performed one hour after study drug administration. After 
an overnight fasting period, patients consumed a standardized breakfast containing 
approximately 618 kcal, which was composed of 65% carbohydrates, 17% proteins, and 
18% lipids. Before breakfast intake, 4 blood samples were collected for determination of 
baseline blood glucose and serum insulin levels. After breakfast intake, blood samples 
for determination of blood glucose and serum insulin levels were collected at 15-minute 
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intervals over a period of 4 hours. Blood glucose was measured using a laboratory 
device based on a glucose oxidase method (Super GL analyzer, Hitado, Moehnesee-
Dellecke, Germany). Serum insulin levels were measured by the local laboratory using 
a radio immuno assay. 
Additional metabolic assessments 
For calculation of the HOMA insulin resistance score (HOMA-IR score), which is a 
measure of insulin sensitivity, fasted venous blood glucose and serum insulin levels 
were determined at baseline (Visit 1) and after 15, 28, and 29 days of treatment (Visit 2, 
3, and 4, respectively) under fasted conditions.  
When not in clinic, for evaluation of daily blood glucose levels, patients performed 
SMBG by measurement of pre-meal blood glucose values three times a day during the 
whole course of each treatment period using a point-of-care blood glucose meter 
(Glucometer, Bayer Leverkusen, Germany). 
Pharmacokinetic sampling 
Venous blood samples were collected immediately prior to study drug intake and 0.33, 
0.67, 1, 1.5, 2, 3, 4, 6, 8, and 12 h thereafter on Day 29. Plasma was separated and 
frozen at -20 ºC until assayed. Plasma concentrations of palosuran were determined 
using a validated liquid chromatography assay coupled to tandem mass spectrometry 
operating in the positive ionization detection mode. The limit of quantification was 1.0 
ng/ml (between-run coefficient of variation below 9.3%). 
Safety and tolerability assessments 
Tolerability and safety were evaluated using spontaneously reported adverse events 
(AEs), physical examination, measurements of vital signs (supine systolic and diastolic 
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blood pressure, and pulse rate), ECG and laboratory test parameters (including 
fructosamine, HbA1C, and insulin), performed before, during, and after the study. For 
safety reasons, blood glucose was measured for 4 hours on the first day of each 
treatment period. 
Data analysis 
All calculations of the area under the concentration versus time curve (AUC), which is a 
measure to express overall drug effect, were performed using the linear trapezoidal 
method. 
From the hyperglycemic glucose-clamp, the first- and the second-phase insulin 
response, the AUC of serum insulin levels during the clamp, and insulin sensitivity as 
assessed as total of glucose consumption were derived. Second-phase insulin 
secretion, the primary variable in this study, was calculated as the difference from 
baseline (defined as the mean of pre-infusion values) in the incremental insulin 
response during the last hour of the hyperglycemic glucose-clamp (expressed as 
absolute and % change). Likewise, total serum insulin AUCs during the hyperglycemic 
glucose-clamp were also baseline corrected. The occurrence of a first-phase insulin 
response was assessed before unblinding of the study. Glucose consumption during the 
hyperglycemic glucose-clamp was calculated by plotting the glucose infusion rate (GIR) 
per kilogram bodyweight versus time and determining the AUC. 
From the meal tolerance test results, blood glucose and insulin levels were assessed by 
calculating the baseline-corrected (defined as the mean of the values before breakfast 
intake) AUC of blood glucose and serum insulin, respectively. HOMA-IR was calculated 
as fasting serum insulin level [μU/ml]*fasting blood glucose [mmol/l])/22.5 [26,27]. 
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From the SMBG results, the AUC of the fasted blood glucose values during the study 
was calculated, standardized for 27 days.  
Calculation of model-independent pharmacokinetic parameters for palosuran was 
performed using Professional WinNonlin Version 4.0.1. (Pharsight Corporation, 
Mountain View, USA). The maximum plasma concentration (Cmax) and the time of its 
occurrence (tmax) were obtained from individual data. The area under the plasma 
concentration versus time curve during one dosing interval of 12 h (AUCτ) was 
calculated.  
Statistical analysis 
The sample size of 20 patients was calculated on the basis of detecting a change of 
30% in mean incremental second-phase insulin response using the Wilcoxon signed-
rank test with a 2-sided Type I error of 5% and a power of 90%.  
To explore differences between treatments on the hyperglycemic glucose-clamp, meal 
tolerance test, and additional blood glucose parameters, the two-sided Wilcoxon signed-
rank test was used. All variables other than the second-phase insulin response were 
statistically analyzed in an exploratory fashion and, therefore, no correction for multiple 
testing was performed. 
Results 
Twenty-one patients were included in the study, received treatment with study drug and 
of these patients, twenty completed the study according to the protocol. One patient 
was withdrawn from the study due to an adverse event and was, therefore, only 
analyzed for safety (more details are provided below). Demographic characteristics of 
the per-protocol group at screening are summarized in Table 1.  
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During the hyperglycemic glucose-clamps the blood glucose target of 240 mg/dl was 
rapidly reached and maintained throughout the glucose-clamp assessment (Figure 1). 
The mean insulin concentration-time profiles during the hyperglycemic glucose-clamp 
for each treatment are displayed in Figure 2, showing no difference for palosuran versus 
placebo. The second-phase insulin response of each treatment and the difference 
between treatments during the glucose-clamp are presented in Table 2.  
Treatment with palosuran did not affect the second-phase insulin response (primary 
endpoint). In addition, the insulin levels and exposure to insulin expressed in AUC 
(Table 2) during the glucose-clamp were comparable between treatment with palosuran 
and placebo. 
A first-phase insulin response was identified in only 8 patients (40% of the per-protocol 
population).  
 
Table 1 Demographic data summary. 
Per protocol population N = 20 
Male / Female [n (%)]                        16 (80.0) / 4 (20.0) 
Age* [years (SD)]    53.7 (7.5) 
Body weight* [kg (SD)]     88.8 (11.1) 
BMI [n (%)] 
      Normal           (18.5 - 24.9 kg/m2) 
      Overweight    (25.0 - 29.9 kg/m2) 
      Obese            (> 30.0 kg/m2) 
 
         2 (10.0) 
        11 (55.0) 
          7 (35.0) 
Waist-to-hip ratio* (SD)      1.0 (0.1) 
HbA1C*  [% (SD)]      6.4 (0.8) 
  
Data are expressed as arithmic means. 
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Palosuran showed no effect on any of the secondary efficacy parameters, i.e., glucose 
consumption during the hyperglycemic glucose-clamp (Figure 1 and Table 3), meal 
tolerance test parameters (Figure 3), changes in insulin sensitivity measured by HOMA-
IR score (Table 4) and AUC of the SMBG (Table 3). No effects on fructosamine levels 
were detected during this study.  
The mean plasma concentration-time profile of palosuran in diet-treated patients with 
type 2 diabetes mellitus in this study is shown in Figure 4. Geometric mean Cmax, and 
AUC (95% confidence interval) and median tmax (range) values in this patient 
population were 180 (125, 260) ng/ml, 581 (422, 800) ng.h/ml, and 3.0 (0.67, 4.3) h, 
respectively. The plasma concentration-time profile in this patient population can be 
characterized by rapid absorption with a peak at approximately 1 hour. Some patients 
showed a second peak between 3 and 4 hours after drug administration. 
Figure 1 Arithmetic mean (± SD) of glucose infusion rate per kilogram 
bodyweight (lower) and blood glucose (upper) vs. time during 
the hyperglycemic glucose-clamp test (n = 20). 
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Table 2 Insulin response during the hyperglycaemic glucose clamp. 
Treatment Second-phase insulin response  
[μU/ml (95%Cl)] 
Second-phase insulin response  
[% change (95%Cl)] 
Total AUC of insulin  
[μU.min/ml (95%Cl)] 
Palosuran 37.5 (24.3, 50.7)    400 (260, 541)   3284 (2076, 4492) 
Placebo 39.3 (25.7, 52.9)    372 (256, 489)   3472 (2225, 47120) 
    
Differences between 
palosuran and placebo 
-1.8 (-7.8, +4.2)    28.1 (-59.6, +116)    -188 (-760, +383) 
 
 
Data are expressed as arithmetic means. No statistically significant difference was observed between palosuran and 
placebo. 
Figure 2 Arithmetic mean (± SD) concentration-time course of insulin 
during the hyperglycemic glucose-clamp test (n = 20). 
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Table 3 Results of the hyperglycaemic glucose clamp, the meal 
tolerance test, and self-monitoring of blood glucose. 
 
Treatment Glucose consumption 
during the hyperglycemic 
glucose-clamp 
[mg/kg (95%Cl)] 
Blood glucose levels in 
meal tolerance test 
[mg.min/dl (95%Cl)] 
Insulin secretion in 
meal tolerance test 
[μU.min/ml (95%Cl)] 
AUC of fasted, pre-meal 
blood glucose recorded by 
patients during the study  
[mg.day/dl (95%Cl)] 
Palosuran   832 (744, 920) 4693 (2896, 6490)  8363 (6936, 9790) 3450 (3212, 3688) 
Placebo   862 (738, 986) 4511 (2838, 6184)  9478 (7381, 11576) 3505 (3195, 3816) 
     
Difference between 
palosuran and 
placebo 
-29.5 (-131, +71.6)   182 (-1129, +1493) -1115 (-2456. +226) -55.8 (-184, +72.9) 
 
 
Data are expressed as arithmetic means. No statistically significant differences were observed between palosuran and 
placebo. 
Figure 3 Arithmetic mean (± SD) concentration-time courses of blood 
glucose (left) and insulin (right) during the meal tolerance test 
(n = 20).  
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Of the 21 patients, while treated with palosuran, 9 reported a total of 12 AEs. One of the 
patients was withdrawn from the study on Day 17 of the first treatment period due to a 
severe case of collapse. Though a relationship of this AE to palosuran cannot be 
excluded, the patient reported to have had previous experience of collapses before start 
of the study. Of the 20 remaining patients, while treated with placebo, 11 reported a 
Figure 4 Arithmetic mean plasma concentration (SD) versus time profile 
(0 - 12 hours) of palosuran in patients with diet-treated type 2 
diabetes mellitus (n = 20) after 4 weeks of treatment with 
palosuran 125 mg b.i.d. 
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Table 3 Insulin sensitivity expressed as homeostatis model 
assessment-insulin resistance score. 
 
Day Palosuran [μU.ml-1.mM (SD)] Placebo [μU.ml-1.mM (SD)] 
  1 2.3 (1.5) 4.4 (5.2) 
15 4.0 (4.8) 4.1 (4.2) 
28 3.0 (1.6) 3.7 (2.6) 
29 2.8 (1.4) 4.5 (4.1) 
  
Data are expressed as arithmetic means.  
Part III: Clinical Pharmacology of palosuran  
             in Type 2 DM patients  
Chapter 7.  Effects of palosuran on insulin secretion 
 
146 
total of 17 AEs. Mild to moderate headache was the most commonly reported AE, all 
other AEs were mostly reported once or twice and were of mild to moderate intensity. 
Except for one mild case of aptyalism ("dry mouth") at night, all AEs resolved without 
sequelae. No effects of palosuran on hematology and biochemistry parameters, 
urinalysis, vital signs, body weight, physical examination, or ECG parameters could be 
detected. 
Discussion 
In animal models of diabetes, palosuran, a potent and selective UT-receptor antagonist, 
significantly improved survival of the rats and reduced hyperglycemia, serum 
cholesterol, triglyceride, and HbA1C levels compared to untreated rats [22]. However, in 
humans the function of the U-II system has not yet been elucidated and is complicated 
by the fact that effects of U-II differ between species and vascular beds [13,28,29]. On 
the basis of the observation of high U-II levels in patients with diabetes mellitus, we 
investigated for the first time the effects of the U-II receptor antagonist palosuran in this 
patient population.  
Our main focus in this study was to investigate the effects of palosuran on insulin 
secretion and sensitivity. Therefore, the change in second-phase insulin response 
during the hyperglycemic glucose-clamp was chosen as the primary efficacy endpoint. 
The hyperglycemic glucose-clamp is considered as gold standard to evaluate β-cell 
function [6,30]. Although a more laborious procedure, this method shows good 
reproducibility with within-subject variations below 10%, can focus on specific aspects of 
insulin action by adapting the concentrations of glucose and insulin, can be combined 
with various other techniques (e.g., tracers), and is not influenced by factors such as gut 
hormones and neural stimulation. A drawback of this method is that the glucose level is 
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raised to a higher level than that found in normal physiology and that it requires 
specialized equipment and personnel [31,32]. In this study we observed that palosuran 
did not affect the second-phase insulin response, neither in terms of absolute nor as 
percentage difference from baseline. Also no effect on the first-phase insulin response 
was detected, although only a part of the patients (40%) had a pronounced first-phase 
rise in insulin. In addition, no effects on the glucose infusion rate, or total AUC of insulin 
were detected during treatment with palosuran. 
To explore the effects of palosuran under more physiological conditions, we also 
assessed β-cell secretory capacity with a meal tolerance test, in which glucose and 
insulin levels were measured after the administration of a standardized meal. In line with 
the findings of the hyperglycemic glucose-clamp, palosuran did not affect the insulin or 
glucose levels during the meal tolerance test. Interestingly, when comparing the insulin 
response, insulin levels during the meal tolerance test were in general higher than 
during the glucose-clamp, whereas in some patients the insulin response was marginal. 
This last observation indicates that factors other than the intravenous glucose stimulus 
alone influence insulin release from pancreatic β-cells after a meal. These factors could 
be the incretin peptide hormones such as glucose-dependent insulinotropic polypeptide 
(GIP) and glucagon-like-peptide-1 (GLP-1). These hormones are released in the 
intestine only in response to nutrient ingestion and stimulation of the gastrointestinal 
tract, hence the additional effect on insulin secretion is not observed during the 
hyperglycemic glucose-clamp [33-35]. These results suggest that although the 
hyperglycemic glucose-clamp is a reliable, reproducible method to assess β-cell 
function, the meal tolerance test provides useful additional insight into the normal 
physiology of diabetic patients.  
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We further investigated insulin sensitivity, assessed both by glucose consumption 
during the hyperglycemic glucose clamp and HOMA-IR score and glucose levels during 
28 days of treatment. Though the euglycemic glucose-clamp is the gold standard to 
assess insulin resistance, HOMA-IR scores are highly correlated with euglycemic 
glucose-clamp results [36]. No differences were observed between palosuran and 
placebo. It is noted that there was a difference between values at baseline and at end of 
treatment between palosuran and placebo (Table 4). This might be due to variation in 
HOMA, which is dependent on the number of fasting samples obtained and type of 
insulin assay used. Evaluation of the data using a log transformation approach as 
suggested by Muniyappa et al. shows that, the differences observed in this study are of 
no relevance [27] 
The mean plasma concentration-time profile of palosuran in diet-treated patients with 
type 2 diabetes mellitus was similar to that of healthy subjects [24]. However, when 
reviewing the individual profiles it was observed that only few patients had the typical 
second peak that was observed in healthy subjects. The plasma concentration-time 
profile in patients showed a peak at approximately 1 hour after study drug 
administration, ensuring sufficient exposure to palosuran at the time of the 
hyperglycemic glucose-clamp and meal tolerance test. It was observed that the 
exposure to palosuran in this patient group was quite variable. Compared to a historical 
group of healthy subjects the Cmax and AUCτ of this patient population showed an 
overall decrease in exposure of approximately 50% [24].  
Palosuran was well tolerated, in line with previous observations in healthy subjects and 
in a pilot study in patients with diabetic nephropathy [23-25]. No serious adverse events 
were reported. The most frequently reported AE was headache. The incidence of AEs 
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reported during treatment with palosuran was similar compared to placebo. No clinically 
relevant changes in vital signs, ECG, and clinical laboratory parameters were observed. 
For HbA1C  as a marker of glycemia this was expected as changes can only be seen 
after several months of treatment [37,38]. However, as fructosamine is a marker of 
blood glucose levels in the preceding 2-3 weeks, it was confirmed that palosuran does 
not influence glycemia [37,38]. 
From the results of this study we can conclude that neither under hyperglycemic 
glucose-clamp conditions nor during a more physiological meal test approach, 
palosuran had an influence on insulin secretion in diet-treated patients with type 2 
diabetes. Also, no signs on insulin sensitivity or glucose levels during the treatment 
period of 28 days could be observed. 
Due to the absence of any effects on insulin and glucose regulation parameters, it could 
be hypothesized that the exposure to palosuran was too low to invoke an effect and that 
dose adjustment would have been required in this patient group. However, in a study 
with type 2 diabetic nephropathy patients exposure to palosuran was comparable to our 
patient group, whereas in that study a significant decrease in 24 h-urinary albumin 
excretion rate was observed [25]. Furthermore, Clozel et al. showed a significant 
decrease in U-II induced contraction at 1 μM palosuran in a rat assay that assessed the 
functional selectivity of palosuran for the UT receptor [21]. Taking into account the 
10−fold difference in inhibitory potency on the human compared to the rat UT receptor, 
this would translate in a concentration of approximately 50 ng/ml, which is well covered 
by the concentrations found in patients in this study. Therefore, we believe that a dose 
of 125 mg palosuran b.i.d. was sufficient to investigate the objectives of this study.  
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Another factor could be that the secretory capacity of insulin in the study population was 
too low. Indeed, only 40% of the included patients had a first-phase insulin response. 
However, this observation is in line with the current knowledge of insulin secretion in 
type 2 diabetes mellitus patients; a reduction or loss of the first-phase insulin response 
is one of the first characteristics of the disease [7,9,39] and does not necessarily impair 
the second-phase insulin response, which was the primary efficacy endpoint. 
Additionally, in a study performed by Rizzo et al., an effect of repaglinide on insulin 
secretion in a hyperglycemic glucose-clamp could be demonstrated in a similar patient 
population group, with similar serum insulin levels [40]. 
In diabetic rats, palosuran has been demonstrated to have acute and chronic effects on 
glucose control. Acutely, palosuran decreased serum glucose and increased insulin in 
response to a glucose load, suggesting that palosuran has a direct effect on release 
and/or production of insulin in diabetic rats [22]. Palosuran is a selective antagonist of 
the human UT-receptor with an in vitro activity about 300-fold greater than on the rat 
receptor. As our data show that in humans, antagonism of the U-II receptor does not 
affect insulin secretion, this finding suggests that the U-II system has a different function 
in humans. In animals, in addition to the direct effect on insulin secretion, palosuran 
could be beneficial by attenuating the increased sympathetic activity of diabetes. Data in 
animals have shown that exogenous U-II increases sympathetic activity by increasing 
circulating catecholamines and cortisol and stimulating fatty acid release [41,42]. It 
would be of interest to investigate whether U-II in man also has an effect on sympathetic 
activity, and whether antagonism of the UT-receptor would be beneficial in patients in 
whom sympathetic activity is increased.  
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In the present study plasma U-II concentrations were not determined. Therefore, it could 
be that the study participants did not have elevated U-II levels and, thus, antagonism of 
the UT-receptor would not elicit an effect. Although possible, we believe that this is 
unlikely given the fact that a clear relationship between diabetic state and elevated U-II 
levels has been observed [43,44].  
In conclusion, although there are strong indications that the U-II system is involved in 
the pathogenesis of type 2 diabetes mellitus, and beneficial effects of palosuran have 
been observed in rat models, palosuran did not show any effects on insulin and glucose 
regulation (measured with a hyperglycemic glucose-clamp and meal tolerance test) in a 
diet-treated patient population. Also in terms of insulin sensitivity, as assessed with 
HOMA-IR score, no differences between palosuran and placebo were observed. 
Palosuran does not appear to represent a new treatment strategy in diet-treated 
patients with type 2 diabetes mellitus. More research is needed in order to understand 
the role of urotensin-II and its receptor in diabetes mellitus and to unravel the apparent 
discrepancy between animal and human observations.  
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Urotensin: functional or fishy? 
Research on the function of Urotensin-II (U-II) and its receptor (UT receptor) has taken 
a flight after its discovery in humans in the late nineties. First thought to be a peptide 
purely existent in lower animal species, predominantly fish, since then the peptide has 
been identified in various mammalian species. With U-II and the UT receptor expressed 
in various tissues (e.g., heart, lung, kidney, spinal cord) and the finding that U-II is a 
more potent vasoconstrictor than endothelin-1, the U-II system as a target for various 
diseases holds a promise that has not been fulfilled so far.  
Besides its effect on blood vessels, U-II has other regulatory effects as discussed in 
Chapters 1 and 2 and summarized in Figure 1. Several functions of U-II are conserved 
across species, although conflicting responses to U-II also have been reported. Unlike 
endothelin-1, the response to U-II appears to be dependent on many factors such as 
the source of U-II used and the species investigated, as well as the vascular bed and 
vessel types studied. Partly due to this, it remains unclear whether U-II has a 
detrimental or protective function. It has been suggested that elevated U-II plasma 
levels could serve as a marker for disease progression. However, in recent studies, high 
levels of U-II could also be correlated to protective effects (Chapter 1).  
What is the potential of the selective urotensin-II receptor 
antagonist palosuran in the treatment of metabolic and renal 
disease? 
Numerous studies have suggested a role of U-II in glucose regulation through actions 
on pancreatic cells and stimulation of the central nervous system (Chapter 1) as well as 
controlling cardiovascular homeostasis through the kidney (Chapter 2).  
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Thus, a disruption of the U-II system could contribute to metabolic and renal disease 
such as Type 2 diabetes mellitus (Type 2 DM) and diabetic nephropathy. 
 
With a rapidly increasing number of patients worldwide suffering from Type 2 DM, the 
increased risk of concomitant cardiovascular disease, and the drawbacks of current 
diabetic medications, there is a need for an effective and safer treatment (Introduction).  
Figure 1 Biological actions of human Urotensin-II on major organ 
systems.  
Heart 
•Coronary vasoconstriction
•Positive inotropism
•Reflex tachycardia
•Cardiomyocyte hypertrophy
•Fibrosis
•Aberrant Ca2+ handling
CNS 
•Increased sympathetic 
outflow (through plasma 
adrenaline, ACTH)
•Increased BP and HR
•Increased TSH and prolactin
Peripheral vasculature 
•Vasoconstriction
•Vasodilatation (NO, PGI2, EDHF)
•Smooth muscle cell mitogenesis
•Enhanced plasma extravasation 
(through endothelial inflammation) 
Kidney 
•Decreased renal blood flow
•Altered Na+ excretion
•Increased epithelial cell 
proliferation
Pancreas
•Decreased glucose-induced 
insulin secretion
Human
urotensin-II
 
ACTH = adrenocorticotropic hormone; BP = blood pressure; CNS = central nervous system; EDHF = endothelial derived 
hyperpolarization factor; HR = heart rate; NO = nitric  oxide; PGI2 = prostacyclin; TSH = thyroid-stimulating hormone 
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Palosuran, a non-peptide, orally active, selective, potent, and competitive antagonist of 
the U-II receptor (UT receptor), developed by Actelion Pharmaceuticals Ltd, proved in 
rat models of diabetes to improve pancreatic and renal function and increase survival 
(Chapter 2).  
In healthy subjects, palosuran was well tolerated after single- and multiple-dose 
administration over a wide dose range. The pharmacokinetics were indicative of a twice 
daily dosing regimen. Two absorption peaks could be detected at approximately 1 and 4 
h after drug administration. Following this, elimination was biphasic with a faster and 
slower elimination phase resulting in low plasma concentrations at 12 h after drug 
administration (Chapter 3 and 4). The intake of food had a minor effect on drug 
exposure expressed in area under the curve (AUC), but is not considered to be of 
clinical relevance. However, the double-peak phenomenon as well as differences in 
morning and evening trough concentrations may be, in part, caused by the intake of 
food (Chapter 5). With increasing dose, a more than dose-proportional increase in 
palosuran exposure (expressed as maximum concentration and AUC) occurred. 
Although no treatment- or dose-related patterns in adverse events, vital signs, clinical 
laboratory, or ECG parameters were observed, a dose of 125 mg b.i.d. was selected for 
further clinical development to allow for an additional margin of safety. In addition, no 
pharmacodynamic markers could be identified in healthy subjects that could guide dose 
selection for patient studies (Chapter 3 and 4).  
In an exploratory pharmacodynamic study in hypertensive patients with diabetic 
nephropathy it was shown that 125 mg palosuran, given b.i.d. for 13.5 days on top of 
existing blood pressure lowering medications, decreased 24-h urinary albumin excretion 
rate (24-h UAER), a clinical marker for cardiorenal disease (Chapter 6). Surprisingly, in 
this study, no effects on other renal hemodynamic parameters (i.e., glomerular filtration 
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rate, renal blood flow, filtration fraction) were observed, which hampers the 
understanding of the mechanism underlying the reduction of 24-h UAER. It is thought 
that concomitant medications may have masked certain effects of palosuran on renal 
hemodynamic parameters (Chapter 6) but further studies are needed to validate the 
effects seen in this trial. Up to date, only one other study has been conducted in an 
attempt to confirm these study results, without success [1]. The study of Vogt et al. 
investigated the effect of palosuran on 24-h UAER and systemic blood pressure in 62 
patients with diabetic nephropathy, using a multi-center, randomized, double-blind, 
placebo-controlled, 2-period crossover design. Additionally, renal hemodynamic 
parameters were measured in a sub-study. In this study, it was shown that 4 week 
treatment with 125 mg palosuran b.i.d. did not show any effect on 24-h UAER or blood 
pressure. In the sub-study no effects on renal hemodynamic parameters were 
observed. Whether the observations were due to insufficient exposure to palosuran, 
masking of effects by concomitant medication, or other factors, deserves to be further 
investigated [1]. 
Palosuran was also investigated in a single-center, randomized, double-blind, placebo-
controlled, 2-period crossover design study in twenty patients with Type 2 DM (Chapter 
7). The aim of this proof-of-concept study was to evaluate the effect of a 4-week 
treatment with 125 mg palosuran b.i.d. on blood glucose and insulin levels after 
hyperglycemic glucose-clamp and a meal tolerance test. In the study, no clinically 
relevant effects of palosuran on any parameters were observed, indicating that 
palosuran may not be beneficial in treatment of Type 2 DM (Chapter 7). 
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Future perspectives and conclusions 
The results described in this thesis show that palosuran, an orally active, selective, UT 
receptor antagonist has no clinically relevant effects in patients with diabetic 
nephropathy and Type 2 DM. The drug was well tolerated at a total daily dose of 250 
mg for a period of 4 weeks. Given the discrepancy between the results of preclinical and 
clinical studies, several questions remain deserving further investigation. 
I. Was the exposure sufficient in clinical studies?  
Clinical research was limited to 4 weeks due to the available toxicology data at the time. 
Although it cannot be excluded that a longer duration of treatment would have resulted 
in a better effect, in the absence of any trends in the double-blind diabetic nephropathy 
and Type 2 DM studies, it is not considered to be a relevant study limitation. From pre-
clinical experiments it was estimated that a clinically relevant dose would be between 50 
and 125 mg palosuran [2]. It is known that direct translations from animal models to 
humans may not be reliable, specifically in the absence of a robust pharmacodynamic 
marker. With a number of tools available to predict the efficacious dose better [3], 
further research is needed to identify pharmacodynamic markers that could be utilized 
in animals as well in humans.  
II. Was the choice of Type 2 DM an appropriate target population for a proof-of-concept 
study? 
Diabetes is a complex metabolic disease that undergoes several stages that cannot be 
clearly distinguished [4]. In practice, the progression from pre-diabetes (also known as 
impaired glucose or impaired insulin tolerance) to Type 2 DM is a gray area for which 
the diagnostic criteria and classification have been frequently revised in the past 50 
years [5-7]. In fact, the hyperglycemic clamp data in subjects in the Type 2 DM study 
General Discussion  
 
163 
demonstrated that there is no 'typical' profile for Type 2 DM patients [8]. It may be that 
the U-II mechanism is not relevant at all stages of diabetes, thus the choice of a broad 
target population may have masked effects of palosuran. Clarifying the exact role of U-II 
and a choice for a sub-population of Type 2 DM patients by setting boundaries for blood 
glucose, HbA1C or limiting the time since diagnosis may provide further insight into the 
utility of UT receptor antagonists in metabolic disease. 
III. What is the role of U-II-related peptide (URP) in the U-II system? 
While not discussed in detail in this thesis, after discovery of U-II a peptide analog 
termed U-II-related peptide (URP) was found first in rat brain [9-11], and later in other 
mammalian species [12]. While the function of URP appears largely the same as that of 
U-II, distinct differences in biological effects have been observed suggesting that they 
could also have different pathophysiological roles in disease [12]. Palosuran may have 
not been sufficiently selective, which may have contributed to the observed lack of 
effect in the clinical studies. 
IV. Are there more promising indications for UT receptor antagonists? 
Besides the renal and metabolic system, the UT receptor is widely expressed in the 
cardiovascular, pulmonary, and central nervous system (Chapter 1), which indicates 
that UT receptor antagonism can be useful in other indications than Type 2 DM and 
diabetic nephropathy. An upcoming indication of interest is pulmonary arterial 
hypertension (PAH). PAH is a disease that is associated with structural changes in both 
the pulmonary vasculature and the right heart ventricle. Changes involve three 
combined elements: vasoconstriction, vascular-wall remodeling, and thrombosis in situ 
[13]. Current therapies have targeted three major pathways (i.e., the prostacyclin 
pathway; the endothelin pathway; and the nitric oxide pathway) [14]. U-II is much more 
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potent than endothelin-1 [15] and UT receptor antagonists are believed to have 
vascular-wall remodeling properties through effects on the nitric oxide and endothelin 
pathways [16,17]. Indeed, recent data in animal models suggested that palosuran could 
provide benefit in the of treatment PAH as well as scleroderma, another disease 
associated with vascular alterations [18,19]. Last but not least in vitro data shows that 
U-II is expressed in a number of tumor tissues including adrenocortical tumors and 
neuroblastomas [20-23], which broadens the potential use of UT receptor antagonists.  
In conclusion, while studies performed with palosuran have not shown efficacy in 
subjects with diabetic nephropathy and Type 2 DM, there is enough reason to believe 
that UT receptor antagonists can have therapeutic value in various other cardiovascular, 
pulmonary, renal, and oncologic indications. More insight in the U-II mechanism as well 
as clinical data is needed. 
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